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The 2015 American Heart Association scientific statement has advocated for sex- 
specific research to understand the paradoxically higher sensitivity of women to type 2 
diabetes mellitus (T2DM)-associated cardiovascular morbidity and mortality. The 
primary goal of this study was to address this need by elucidating the mechanisms by 
which these females lose inherent cardioprotection and become more susceptible to 
detrimental cardiovascular-related outcomes than males. The central hypothesis of this 
study was “estrogen (E2) exacerbation of diabetes-evoked disruption of cardiac 
adiponectin (APN)-connexin 43 (Cx43) signaling underlies heightened myocardial 
dysfunction in diabetic females”.  The study provides novel data on the modulation of 
the cardiac E2-APN-Cx43 axis and its critical role in maintaining a delicate redox 
balance in cardiomyocytes, how this cardioprotective signaling becomes detrimental in 
T2DM, and identified a molecular target for developing potential pharmacological 
interventions for diabetic females.  Our findings demonstrate that E2 exacerbates female 
autonomic and cardiac dysfunction in a rodent model of T2DM, increasing left 
ventricular (LV) mass and Tau as well as decreasing LVDP, dP/dtmax, dP/dtmin, 
contractility index (CI) and fractional shortening (FS). Additionally, the restoration of the 
APN-Cx43 signaling axis via a small molecule APN agonist virtually reverses all of 
these cardiac dysfunction parameters as well as mitigates detrimental molecular 
alterations and a proinflammatory milieu in all female rats by restoring cardiac levels of 
Cx43, decreasing heme oxygenase 1 (HO-1), tumor necrosis factor (TNF) α and 
circulating levels of asymmetric dimethylarginine (ADMA).  The research project 
replicates the unexplained paradoxically higher mortality risk in women and provides 
novel mechanisms for this cardiovascular health problem.  Collectively, these findings 
support the hypothesis and proposed underlying mechanism and further demonstrations 
that the restoration of Cx43 emerges as a promising novel target in diabetic 
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CHAPTER ONE: GENERAL INTRODUCTION 
 
1.1 Scientific Premise 
Recent scientific statements from both the National Institutes of Health (NIH) and 
American Heart Association (AHA) have highlighted the need for conducting preclinical 
female sex specific research. Specifically, there is a need to understand the 
mechanisms underlying a paradoxical increase in the cardiovascular morbidity and 
mortality in women with type 2 diabetes mellitus (T2DM) compared with age-matched 
diabetic men (Regensteiner et al., 2015). T2DM is increasing at a rapid rate in younger 
individuals, and its treatment constitutes a significant financial burden (Regensteiner et 
al., 2015). Physiologically, premenopausal women lose their inherent cardioprotection, 
and are more impacted by the diabetes-associated cardiovascular anomalies when 
compared to age-matched T2DM men (Juutilainen et al., 2004).  A recent report 
showing no negative cardiovascular consequences of estrogen (E2) replacement 
therapy (ERT) in women (Manson et al., 2017) will likely increase future ERT. Thus, this 
preclinical research focused on elucidating the mechanisms by which ovarian 
hormones, particularly estrogen (E2), render females more susceptible to diabetes 
mellitus (DM)/hyperglycemia-related cardiovascular anomalies than males. The findings 
will also yield new insights into the unstudied mechanisms of E2-mediated upregulation 
of adiponectin (APN)-connexin 43 (Cx43) function in females under physiological 
conditions and how its disruption in pathological states, such as T2DM, contributes to 
this unexplained paradox.  The restoration of this critical signaling axis emerges as a 
novel and effective therapeutic target in diabetic females.   
2 
 
1.2 Adiponectin (APN) 
APN, an adipokine with anti-inflammatory and antidiabetic properties (Guo et al., 
2007; Durand et al., 2012; Fisman and Tenenbaum, 2014), is reduced in obesity, 
T2DM, and coronary artery disease (Kadowaki et al.; Takemura et al., 2007; Zhu et al., 
2008; Tian et al., 2009; van Stijn et al., 2015) and binds to two transmembrane 
adiponectin receptors, AdipoR1 and AdipoR2.  Sexual dimorphism showing higher APN 
levels and APN protection of left ventricular (LV) function from oxidative stress in eNOS 
deficient mice (Durand et al., 2012) support a greater cardioprotective role for APN in 
female mice. This premise is further supported by the ability of APN supplementation, in 
aged female rats and porcine models, to reduce infarct size (Tomicek et al., 2015) and 
oxidative stress (Tao et al., 2007). However, it remains unstudied if this sexually 
dimorphic cardioprotection, conferred by APN or its downstream effector Cx43, is 
compromised in young DM females. Realizing that cellular oxidative stress transforms 
E2 into a proinflammatory molecule (White et al., 2005), and that DM causes oxidative 
stress (Rochette et al., 2014) and reduces APN, studies are needed to determine if 
these consequences are more prominent in DM females in an E2-dependent manner.  
1.3 Connexin43 (Cx43) 
While Cx43 constitutes a promising therapeutic target for cardiovascular disease 
(CVD) (Schulz et al., 2015), its role in DM associated cardiovascular anomalies in 
females has not been studied. Interestingly, cardiac Cx43 expression and distribution 
are higher in females and its deficiency is implicated in sex-related differences in 
cardiac mortalities (Stauffer et al., 2011; Michela et al., 2015).  Physiologically, Cx43 
3 
 
formation of gap junctions at the outer cardiac sarcolemma ends mediates favorable 
effects on ion flow, energy metabolism, ROS handling and cardiac rhythm (Ruiz-Meana 
et al., 2008). By marked contrast, Cx43 disorganization (lateralization), downregulation 
or reduced phosphorylation (pCx43) creates aberrant hemichannels (Michela et al., 
2015), and leads to cardiac dysfunction (Ai and Pogwizd, 2005) in models of myocardial 
infarction (Ruiz-Meana et al., 2008; Schulz et al., 2015). Therefore, the reliance of 
cardiac function on higher cardiac Cx43 expression in females (Stauffer et al., 2011; 
Michela et al., 2015), likely increases their susceptibility to DM-evoked Cx43 
disorganization and subsequent myocardial oxidative stress and dysfunction. The 
apparent critical role of Cx43 supports the proposed studies to test this hypothesis.  
1.4 Role of E2 in APN-Cx43 signaling in the heart 
Alterations in estrogen receptor (ER) expression (upregulation of ERα) in 
gestational diabetes (Kleiblova et al., 2010) and human heart failure (Mahmoodzadeh et 
al., 2006) may contribute to sex differences in LV hypertrophy and heart failure (Regitz-
Zagrosek et al., 2010).  It is well established that in conditions of oxidative stress, 
estrogen can transform from an anti-inflammatory into a proinflammatory molecule 
(White et al., 2005).  Additionally, ERα KO mice exhibit disrupted APN signaling (Mauro 
et al., 2014) and E2 up- and down-regulates Cx43 and pCx43 expression (Moinfar et al., 
2016) which contribute to cardioprotection (Murphy and Steenbergen, 2014; Murphy et 
al., 2017). Further, E2 regulates nitric oxide synthase (NOS) and numerous calcium 
transporters (Keusch et al., 2008; Murphy et al., 2017) and Cx43 regulates Ca2+ ion 
channel flow in the myocardium (Xiao et al., 2016).  There are no functional or 
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molecular studies on this signaling pathway in DM females. The proposed studies on 
the E2-APN-Cx43 axis are critical to understanding the molecular mechanisms 
underlying exacerbated cardiac dysfunction in DM females, and whether the restoration 
of the function of this axis serves as a novel therapeutic modality for alleviating 
myocardial dysfunction in DM females. 
1.5 An orally active small molecule APN receptor agonist: AdipoRon 
 High molecular weight (HMW) adiponectin mitigates detrimental cardiac 
remodeling in disease states (Takemura et al., 2007; Tian et al., 2009) and exogenous 
HMW APN or globular APN efficaciously represses deteriorating cardiac function (Tao 
et al., 2007; Zhu et al., 2008; Fisman and Tenenbaum, 2014).  Yet, the use of APN as a 
pharmacological therapeutic tool in T2DM is limited due to its short half-life, large size 
and lack of GI absorption (Kadowaki et al.; Zhang et al., 2018). However, AdipoRon, an 
orally available small molecule agonist at AdipoR1 and AdipoR2 (Okada-Iwabu et al., 
2013) constitutes a clinically feasible alternative.  AdipoRon alleviates post-ischemic 
cardiac remodeling and apoptosis in APN KO male mice (Zhang et al., 2015), 
decreases cardiac hypertrophy (Zhang et al., 2018) and mitigates overall DM symptoms 
(Okada-Iwabu et al., 2013; Choi et al., 2018).  Additionally, AdipoRon ameliorated 
diabetic nephropathy and oxidative stress in a male mouse model (Choi et al., 2018). 
However, a potential cardioprotective effect of AdipoRon has not been evaluated in 




1.6 Diabetes Mellitus and Oxidative Stress 
Diabetes Mellitus (DM) is a cluster of metabolic disorders where blood glucose 
levels are elevated over a prolonged period and physiological glycemic control is 
inadequate.  It is caused by absolute or relative insulin deficiency, sometimes 
associated with insulin resistance.  Type 1 diabetes is an autoimmune disease where 
the immune system attacks and destroys pancreatic beta cells.  Type 2 diabetes 
(T2DM) is a syndrome with multiple etiologies rather than a single specific disease.  
However, it is known that as the hyperglycemia of diabetes becomes chronic, the sugar 
that normally serves as a substrate fuel and signal takes on the darker role of toxin in 
the structure and function of organs (Robertson, 2004) and importantly, in the heart 
(Rutter et al., 2003).  This “toxic sugar” creates an overproduction of reactive oxygen 
species (ROS) in the organs and diabetes is well established as a condition of elevated 
oxidative stress (Ceriello and Motz, 2004; Rochette et al., 2014).  
The pathology of DM is a key risk factor for the development of heart anomalies 
and dysfunction and the focus of this research project.  There are key differences 
between the sexes, in large part because of hormonal regulation (Pradhan, 2014), that 
are not fully understood.  The prevalence of DM, a leading risk factor for CVD, is 
increasing at a rapid rate (Regensteiner et al., 2015; Bjornstad et al., 2016) and CVD is 
the leading cause of morbidity and mortality worldwide. Despite the outlined heightened 
risks for female cardiovascular complications and negative outcomes in the diabetic 
population, clinicians are less likely to aggressively treat women with appropriate 
therapeutics as opposed to men (Victor et al., 2012).  Additionally, current 
pharmacotherapies for CVD in the diabetic population have been suggested to be less 
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effective in women than in men (Regensteiner et al., 2015) and mechanisms underlying 
the differential response are undefined.   
1.7 Innovation 
These studies are the first to deal with the mechanisms of the unexplained 
hypersensitivity to myocardial dysfunction in diabetic females. The multilevel approach 
and a well-planned research strategy (longitudinal and cross-sectional design) 
generated first-hand data on the role of the female sex/E2-dependent APN-Cx43 
signaling in regulating cardiac redox status and function in healthy and diabetic females. 
These findings identified a novel molecular target for developing a precision therapeutic 
to alleviate the exacerbated DM-induced myocardial dysfunction in E2-replete females.  
  
1.8 Authentications and Aims of the Study 
The proposed experimental design, validated methods, appropriate sample size 
and statistical analyses led to unbiased robust results. Most notable, selecting 
established conditions for T2DM induction (Srinivasan and Ramarao, 2007; Sasidharan 
et al., 2013) ensures reproducibility of data within and between labs. Scientific rigor was 
ensured by: (i) the use of soy/phytoestrogens-free diets to avoid their confounding 
effects on generated data; (ii) consistent with current recommendations (Griendling et 
al., 2016), at least 2 different methods were used for biochemical measurements of 
oxidative stress markers; (iii) the use of authenticated antibodies and validating their 
specificity in our model system.  
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Specific Aim 1: Test the hypothesis that estrogen exacerbates T2DM-evoked cardiac 
and autonomic dysfunction. 
Rationale: There is unmet need to understand why E2 paradoxically increases 
diabetes-induced cardiac dysfunction. Cardiac remodeling in female mice is more 
exacerbated by decreased APN levels than male mice—suggesting a greater 
cardioprotective role for APN in females (Durand et al., 2012). Whether the reduction in 
cardiac APN in diabetic male rats (El-Sayed et al., 2016) is more evident in diabetic 
female rats needs to be investigated. This is important because there is ongoing debate 
on the role of APN in cardiac pathology in diabetes (Kadowaki et al.) and APN 
interaction with estrogen regulation of nitric oxide synthases (Zhu et al., 2008; Durand et 
al., 2012) and Cx43 (Stauffer et al., 2011). Therefore, the present studies elucidated the 
role of the APN-E2-Cx43 axis in healthy and diabetic female (in the absence or 
presence of E2) and male rats. These integrative studies addressed unresolved 
questions about this clinically important problem impacting women’s cardiovascular 
health. These experiments will address the questions: 
1. Are hemodynamic and cardiovascular dysfunction worse in diabetic estrogen-
replete females? 
2. What are the effects on mean arterial pressure, left ventricular developed 
pressure and contractility? 
3. How are cardiac parameters (dP/dtmax, dP/dtmin, Tau, ejection fraction, fractional 
shortening and autonomic control) affected? 
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4. Does estrogen evoke heightened diabetic glycemic dysregulation and cardiac 
hypertrophy?  Studies will examine glucose tolerance testing and LV 
mass/hypertrophy.  
 
Specific Aim 2: Test the hypothesis that disruption of the APN-Cx43 axis underlies the 
sex/estrogen-dependent exacerbation of diabetic myocardial dysfunction. 
 
Rationale: The dependence of females on higher Cx43 expression to maintain cardiac 
function and redox regulation (Stauffer et al., 2011) may become detrimental in the 
presence of DM. This untested premise is supported if the DM-evoked Cav3 inhibition 
and Cx43 disorganization in male rat hearts (Ruiz-Meana et al., 2008; Michela et al., 
2015; Schulz et al., 2015) is exacerbated in females. Further, it is not known if the ERα 
mediation of the Cav3 dependent disorganization of Cx43 in isolated cardiac myocytes 
(Chung et al., 2009) occurs in DM females. Preliminary data show ERα upregulation in 
DM female rats and previous lab findings implicated ERα in the sex/E2-dependent 
myocardial oxidative stress and dysfunction caused by alcohol (Yao and Abdel‐
Rahman, 2017). These studies focused on the roles of APN, Cx43 and ovarian 
hormones, particularly estrogen, because these molecules are linked, and contribute to, 
cardioprotection under normal physiological conditions (Murphy and Steenbergen, 
2007; Keusch et al., 2008; Murphy and Steenbergen, 2014; Schulz et al., 2015). While 
reported studies in male diabetic rats (Guo et al., 2007; Okada-Iwabu et al., 2013; 
Schernthaner and Stangl, 2013; Fisman and Tenenbaum, 2014; Hossain et al., 2015; 
Koentges et al., 2015; Regensteiner et al., 2015) and our preliminary studies partly 
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support our scientific premise, there are currently no detailed studies on this signaling 
cascade in diabetic female rats, particularly in the presence of estrogen.  These studies 
will address the questions:  
1. Do diabetic females exhibit greater E
2
 dependent disorganization/deactivation of 
cardiomyocyte Cx43 and its signaling cascade?  
I.ERα, ERβ and GPER 
II.APN, AdipoR1 and AdipoR2 
III.Cx43 
2.  Does suppression of downstream cardioprotective molecules of APN signaling 
underlie exacerbated female diabetic myocardial dysfunction? 
I. pAKT/AKT  
II. pERK/ERK 
 
Specific Aim 3: Does restoration of APN-Cx43 signaling (as a novel molecular target) 
reverse heightened female T2DM-evoked cardiac dysfunction? 
Rationale:  The research plan will identify novel molecular targets and add supporting 
evidence to the diabetes evoked disruption of the E2-APN-Cx43 signaling axis as an 
underlying mechanism for female hypersensitivity to cardiovascular dysfunction.  The 
long-term goal focuses on developing precision-based diagnostics and therapeutics for 
mitigating cardiac anomalies in diabetic females. While females produce more super 
oxide, they handle it more efficiently than males, a vital mechanism for their cardio 
protection (Murphy and Steenbergen, 2007; Keusch et al., 2008; Murphy and 
Steenbergen, 2014). These studies focused on restoring the function of the two 
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interrelated molecules APN and Cx43 because they are implicated in this sex-
dependent phenomenon. Notably, APN dampens myocardial oxidative stress (Bugger 
and Abel, 2010; Koentges et al., 2015), at least partly, via triggering Cx43 signaling 
(Murphy and Steenbergen, 2007; Ruiz-Meana et al., 2008; Schulz et al., 2015) and E2 
increases APN and Cx43 levels (Stauffer et al., 2011; Wang et al., 2015). However, the 
possibility that restoring the APN and CX43 function reverses DM-evoked cardiac 
dysfunction in females has not been investigated. The research project applied a 
pharmacological strategy to achieve this goal: administration of the APN agonist, 
AdipoRon (Okada-Iwabu et al., 2013), which also activates Cx43 signaling. These 
studies will address the questions:  
1. Will “AdipoRon” (a small molecule AdipoR1 and AdipoR2 agonist) rescue cardiac 
function in E2-replete diabetic females? Does it ameliorate reduction of 
cardioprotective Cx43, ERK or Akt? 
2. Does restoration of APN-Cx43 signaling (via AdipoRon) reverse oxidative stress 
and other biochemical alterations in E2 replete females? 
3. How are circulating levels of the cardiovascular risk marker, asymmetric 













CHAPTER TWO: MATERIALS AND METHODS 
 
2.1 Animals 
  Young (8 weeks of age) female and male Wistar rats (170-200g, Charles River 
Laboratories, Raleigh, NC) were kept in the University animal care center and housed in 
pairs in standard plastic cages. Rats were allowed free access to water and chow (Prolab 
Rodent Chow; Granville Milling, Creedmoor, NC) until the beginning of the special 
phytoestrogen-free diet.  After initial intake measurements, rodents received ad libitum 
control (AIN-93G Growth Purified diet; 57W5 TestDiet) or high fat (DIO Rodent Purified diet 
with 45% energy from fat; 58V8 TestDiet) diet (Granville Milling, Creedmoor, NC) as 
reported  (Srinivasan and Ramarao, 2007; Brown and Panchal, 2011; Sasidharan et al., 
2013); dietary specifics are included in Table 1. Rats were maintained on a 12-12 hour light-
dark cycle and the temperature was maintained at 23 ± 1 ºC, humidity at 50 ± 10%. All 
surgical procedures were conducted under sterile conditions and rats received preoperative 
analgesia (buprenorphine 0.03 mg/kg every 8 hours, S.Q. or meloxicam 1mg/kg, 0.2ml/day, 
P.O) 30 min prior to surgery.   
  A whole body chamber ventilated with a 1-2% isoflurane, balanced oxygen gas 
mixture was used as anesthesia for the OVX, echocardiography and E2 containing silastic 
tube implantation, while I.P. ketamine/xylazine (90/10 mg/kg, respectively) anesthesia was 
utilized for the terminal femoral and left ventricular catheterization surgery. The 
disappearance of corneal reflex, response to pain sensation (toe pinch) and loss of muscle 
tension were utilized as signs of appropriate anesthesia. Post-operative analgesia consisted 
of a minimum of three days of buprenorphine (0.03 mg/kg/S.Q. every 8 hours) or meloxicam 
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(1mg/kg, 0.2ml/day, P.O). All procedures were approved by the Institutional Animal Care 
and Use Committee and conducted in accordance with the Guide for the Care and Use of 
Laboratory Animals as adopted by the U.S. National Institute of Health and the National 
Research Council Committee Update of the Guide for the Care and Use of Laboratory 
Animals, 2015.  
2.2 Ovariectomy 
Ovariectomy (OVX) was conducted as reported in our previous studies (El-Mas 
and Abdel-Rahman, 2000) in the University Department of Comparative Medicine 
surgical suites under sterile conditions. Rats were placed in a prone position and flank 
shaved with electric clippers. Surgical incision area was prepped with three consecutive 
cleanses of a povidone-iodine scrub, followed with a 70% ethanol rinse. An 
approximately 1-2 cm incision was made in the skin and symmetrical 1 cm incisions on 
either side of the underlying muscle from the second to fifth lumbar vertebrae. The peri-
ovarian fat was pulled out through the muscle incision, ovaries located, tied off with 
sterile suture, and removed. The muscle was closed using absorbable suture (Roboz 
Surgical Instrumental Co., Gaithersburg, MD), skin closed with surgical clips (Mikron 
Precision Inc., Gardena, CA) and removed 10-14 days later. Rats were allowed a two 
week “wash out” period post OVX to ensure depletion of ovarian hormones and most 
endogenous E2 in accordance with an established protocol in our laboratory (El-Mas 
and Abdel-Rahman, 2000).  Estrogen replacement was achieved using subcutaneous 
implantation of silastic tubing (10 mm length, 1.57 mm inner diameter × 3.18 mm outer 
diameter, Silastic®, Dow Corning) filled with approximately 25 mg of 17β-estradiol-3-
benzoate [1,3,5(10)-estratriene-3,17β-diol-3-benzoate]. Silastic tubing was sealed with 
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medical adhesive type A (Silastic®, Dow Corning), gas sterilized, and implanted 
subcutaneously at the back of the neck in rats. Serum estradiol levels were measured at 
the conclusion of the study. 
2.3 Induction of diabetes mellitus (DM) 
  We adopted the high fat diet plus two low doses streptozotocin (STZ) (Brown and 
Panchal, 2011; Sasidharan et al., 2013) to induce T2DM. Four weeks after the initiation of 
the special diet regimen, rats were injected with freshly prepared STZ (35 mg/kg; I.P.) in 
0.1M citrate buffer (pH 4.0) or the buffer (control). One week after the first injection, a 
second STZ injection was given under the same conditions. Three days after the second 
STZ injection, non-fasting blood glucose levels were measured by a Blood Glucose 
Monitoring System (Freestyle-Precision Neo, Abbott, Alameda, CA) with tail vein blood. 
Onset of diabetes was identified by polydipsia, polyuria and BGL ≥ 250 mg/dL. Rats that 
exhibited these characteristics were considered diabetic, and buffer-treated rats were used 
as non-diabetic controls as reported (Srinivasan and Ramarao, 2007).  
2.4 Body and heart weights 
  Body weights were determined, in grams, at baseline (prior to initiation of special diet) 
and then once weekly until the termination of the study. On the final day, prior to vascular 
catheterization, body weights were recorded, and following euthanasia, the hearts were 
excised, weighed and stored at -80ºC for subsequent biochemical studies (see below). 
2.5 Echocardiography 
  Echocardiography was performed at baseline and biweekly by two experienced 
researchers, one of which was blinded to the experimental groups. Both researchers 
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performed echo and analyzed recorded images, with images randomly verified against their 
match. Rats were lightly anesthetized with isoflurane using a whole body chamber ventilated 
with a 1-2% isoflurane, balanced oxygen gas mixture. After anesthesia induction, animals 
were transferred to an imaging platform equipped with a heating pad to maintain body 
temperature and anesthesia maintained via nose-cone delivery of the same gas mixture, 
typically for <10 min. Hair was removed from the chest wall using a chemical depilator and 
the skin cleansed with warm water. Non-toxic acoustic gel was placed on the chest wall and 
non-invasive ultrasound images of the heart were collected and stored for analysis 
according to a standard protocol (Visual Sonics Vevo 2100 (Phase I) and 3100 (Phase II) 
Imaging System, FujiFilm and VevoLab Software v.2.1.0, Toronto, Ontario, Canada). Rats 
were removed from the nose cone, returned to their cage, and monitored until awakened 
spontaneously. M-mode and B-mode images of LV end-diastolic diameter, interventricular 
septum and posterior LV wall thicknesses at end diastole were measured and averaged 
over five beat cycles along with ejection fraction, fractional shortening, contractility index and 
Tau (the mean time constant for the isovolumic-pressure decline).  
2.6 Intravascular and left ventricular catheterization 
  As described in previous studies (Yao and Abdel‐Rahman, 2017), a catheter 
consisting of 5cm PE-10 tubing bound to 15cm PE-50 tubing was placed in the abdominal 
aorta via left femoral artery and a PE-50 tubing, filled with heparinized saline, was inserted 
through the carotid artery into the LV for the measurement of arterial blood pressure and LV 
function, respectively. Hemodynamic recordings were collected when arterial and left 
ventricular catheters were connected to Gould-Statham (Oxnard, CA) pressure transducers 
and flushed with heparinized saline (100 IU/ml). BP and left ventricular indices were 
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simultaneously recorded by ML870 (PowerLab 8/30; Colorado Springs, CO) and analyzed 
by LabChart (v.7) pro software (AD Instruments, Colorado Springs, CO). 
2.7 Blood and tissue collection 
  At the conclusion of hemodynamic measurements, prior to sacrifice, blood was 
collected in heparinized tubes and centrifuged at 2000g for 10 min. Serum was collected 
and stored at -80ºC until biochemical analysis was performed. Rats were euthanized after 
blood collection according to authorized AUP. Hearts were excised, weighed and flash 
frozen in 2-methylbutane (Sigma-Aldrich, St. Louis, MO) on dry ice. Tissue was stored at -80 
ºC until processed for biochemical studies.  
2.8 Western blot analysis 
  All western blots were conducted following the established protocols in our lab (El-
Sayed et al., 2016; Yao and Abdel‐Rahman, 2017). LV tissue was homogenized on ice in 
lysis buffer (20mM Tris, pH 7.5, 150mM NaCl, 1mM EDTA, 1mM EGTA, 1% Triton X-100, 
2.5mM Sodium pyrophosphate, 1mM beta-glycerolphosphate, 1mM activated sodium 
orthovanadate and 1µg/ml leupeptin with a protease inhibitor cocktail (Roche, Indianapolis, 
IN), sonicated and centrifuged (12,000 x g for 20 min). Supernatant protein was extracted 
and samples were quantified for protein using Bio-Rad protein assay system (Bio-Rad 
Laboratories, Hercules, CA). Protein extracts (50 µg/lane) were separated in a 4-12% gel 
electrophoresis (Novex Tris-Glycine gel; Life Technologies, Carlsbad, CA) at 150 V (Bio-
Rad Laboratories, Hercules, CA). After semidry transfer to nitrocellulose membrane for 30 
minutes at 25 V, 1 A (Bio-Rad Laboratories, Hercules, CA), membranes were blocked in 
Odyssey blocking buffer (LI-COR Biosciences, Lincoln, NE) for 2 hours. Post initial blocking, 
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membranes were incubated in primary antibody overnight at 4ºC on a rocker. Primary 
antibodies used were as follows: Rabbit polyclonal anti-APN, anti-AdipoR1, anti-TNFα, anti-
HO-1 and anti-ERα (1:200 dilution, Abcam, Cambridge MA), Rabbit polyclonal anti-AKT and 
anti-pERK (1:200 dilution, Cell Signaling Technology, Danvers MA), Goat polyclonal anti-
Cx43 and anti-GPER (1:200 dilution, Abcam, Cambridge MA) and Mouse monoclonal anti-
GAPDH (1:1000 dilution, Abcam, Cambridge, MA) and Mouse anti-pAKT and anti-ERK 
(1:200 Cell Signaling Technology, Danvers MA). Afterward, secondary membranes were 
washed and incubated with secondary antibody prepared by IRDye680-conjugated goat 
anti-mouse and IRDye800-conjugated goat anti-rabbit, or IRDye680 conjugated donkey anti-
mouse and IRDye800-conjugated donkey anti-goat (depending upon respective primary 
antibody utilized at a dilution of 1:5000) for sixty minutes in the dark at room temperature on 
rocker. GAPDH was used as a loading control.  Molecular weights of proteins for western 
blots are shown, and representative blots for a particular protein in healthy and diabetic 
groups were run on the same gel; whenever random order of the blots necessitated splicing 
gel lanes, this was identified with a gap in the image. Arbitrary units reported are the target 
protein normalized to respective GAPDH on the same gel, or the phosphorylated (pERK and 
pAKT) protein to its respective total protein. Bands were detected by Odyssey Infrared 
Imager and quantified by integrated intensities with Odyssey application software version 3 
(LI-COR Biosciences). 
2.9 Colocalization immunofluoresent microscopy 
 To corroborate western blot findings, spatial distribution of Cx43 was investigated by 
dual labeling immunofluorescence in heart sections as previously described (Steagall et al., 
2017). Briefly, hearts were equlibrated to -20ºC and sectioned with a cryostat (HM 505E; 
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Microm International GmbH, Waldorf, Germany).  Three heart tissue cyrostat sections (20 
µm thick) were post-fixed in 4% paraformaldehyde on Polysine coated microscope slides 
(Thermo Scientific LLC, Portsmouth, NH) and blocked for 2 hours with 10% normal donkey 
serum (Jackson Immunoresearch Laboratories, West Grove, PA) in Tris-buffered saline 
containing 0.1% Tween-20 (TBS) and 10% Triton (X-100). After incubation overnight at 4ºC 
with primary antibody (1:100 dilution v/v), sections were washed four times with TBS and 
incubated with the appropriate secondary antibody (1:200 dilution v/v) for 60 minutes and 
washed four times with TBS. Coverslips were applied with Vectashield mounting medium 
(Vector Laboratories, Inc., Burlingame, CA). Primary antibodies used were goat anti-Cx43 
(Abcam, Cambridge, MA) and mouse anti-Cav3 (Santa Cruz Biotech, CA). Secondary 
antibodies were Cyanine 3 (Cy3)-conjugated donkey anti-goat IgG (H + L) (Jackson 
ImmunoResearch) and Fluorescein (FITC)-conjugated donkey anti-mouse IgG (H + L) 
(Jackson ImmunoResearch). Control sections were incubated with only secondary 
antibodies to determine non-specific staining. Three representative images across the heart 
sections, chosen according to similar spatial orientation, were acquired by laser scanning at 
two wavelengths, 488 nm (Argon/2) and 543 nm (HeNe1), using the Zeiss LSM 700 
confocal microscope.  Image analysis software ZEN 2012 (Carl Zeiss, Jena, Germany) kept 
parameters constant throughout the acquisition process.  
2.10 Measurements of estradiol (E2) 
  For confirmation of the E2 depletion in ovariectomized (OVX) and its restoration to 
physiological levels in OVX rats that received E2 replacement (OVX+E2), E2 levels were 
measured in plasma with a commercially available estradiol ELISA kit (Cayman Chemicals, 
Ann Arbor, MI) according to manufacturer’s instructions.  
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2.11 Heart rate variability (spectral analysis) studies 
In this study, spectral analysis of blood pressure data obtained from healthy, 
vehicle dosed diabetic and AdipoRon dosed diabetic females were recorded by ML870 
(PowerLab 8/30; Colorado Springs, CO) and analyzed by LabChart (v.7) pro software 
(AD Instruments, Colorado Springs, CO). Frequency domain analysis using FFT 
algorithms of RR data series was followed (El-Mas and Abdel-Rahman, 2007).  Spectra 
were integrated into 2 specific frequency bands, low-frequency (LF) (0.25–0.75 Hz) and 
high-frequency (HF) (0.75–3 Hz) bands. To reflect cardiac sympathetic and 
parasympathetic dominance, respectively, the data was expressed as LFnu and HFnu. 
The LF/HF ratio was computed and taken as a measure of cardiac sympathovagal 
balance (El-Lakany et al., 2018). 
2.12 Measurements of Asymmetric Dimethylarginine 
  For indication of cardiovascular risk, Asymmetric Dimethylarginine (ADMA) levels 
were measured in serum, in duplicates, with a commercially available ADMA ELISA rat 
specific kit (MyBioSource, San Diego, CA) according to manufacturer’s instructions.  
2.13 Reactive Oxygen Species (ROS) Measurement 
Oxidative stress level was measured using 2’, 7’-dichlorofluorescein diacetate 
(DCFH-DA), a detector of ROS (Korystov et al., 2009). In summary, a stock solution of  
DCFH-DA (20 mM, Molecular Probes, Grand Island, NY) in DMSO (protected from light) 
was freshly diluted with PBS to prepare a 150 μM working solution. After fresh 
preparation, 10 μl of left ventricular cardiac tissue homogenate supernatant was pipetted 
into a 96-well plate to give a final concentration of 25 μM DCFH-DA to produce 
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fluorescent 2′,7′-Dichlorofluorescein (DCF) in the incubation medium at 37°C. 
Fluorescence intensity was measured after reaction initation using a microplate 
fluorescence reader set at excitation 485 nm/emission 530 nm. The level of ROS was 
determined as relative fluorescence units (RFU) of generated DCF using standard curve 
of DCF production (Fouda and Abdel-Rahman, 2017; Fouda et al., 2018). 
2.14 Intravenous Glucose Tolerance Testing (IV GTT) 
The day before terminal surgery, rats were fasted overnight (approximately 16 h) 
according to approved animal use protocol (AUP). On the morning of terminal surgery, 
animals were anesthetized (as outlined in OVX section) and catheterized for 
hemodynamic measurements. Each rat was given fifteen minutes for continuous data 
recordings to stabilize, and then injected intravenously with a 20% bolus glucose dose 
(2g/10ml/kg; I.V.). Femoral artery blood was analyzed with a blood glucose monitoring 
system (Freestyle, Precision Neo, Abbott, Alameda, CA), and blood glucose levels 
(BGL) were recorded at intervals of baseline (5 min prior to bolus), and post bolus—1 















Table 1 Diet Information  
Diet Protein Fat Carbohydrates Energy 
57W5 (AIN-93G) 
Control Diet 
18.80 % 16.40 % 64.90% 3.90 (kcal/g)2 
58V8 
High Fat Diet 




CHAPTER THREE: ESTROGEN DEPENDENT DISRUPTION OF ADIPONECTIN-
CONNEXIN43 SIGNALING UNDERLIES EXACERBATED MYOCARDIAL 
DYSFUNCTION IN DIABETIC FEMALE RATS  
 
3.1 Abstract 
The reasons for the higher severity of type 2 diabetes (T2DM)-associated cardiomyopathy in 
women, despite their inherent estrogen (E2)-dependent cardioprotection, remain unknown. 
We hypothesized that the reliance of the healthy females’ hearts on augmented adiponectin 
(APN)-connexin43 (Cx43) signaling becomes paradoxically detrimental when disrupted by 
T2DM in an E2-dependent manner. We tested this hypothesis in high fat-low dose 
streptozotocin diabetic rats and their controls with the following designations: (a) sham 
operated (SO); (b) ovariectomized (OVX); (c) ovariectomized with E2 supplementation 
(OVX+E2); and (d) male. E2-replete (SO or OVX+E2) diabetic rats exhibited higher mortality 
and greater increases in left ventricular (LV) mass, and reduced LV developed pressure, LV 
contractility and fractional shortening, but preserved ejection fraction. Further, compared to 
respective nondiabetic counterparts, the hearts of these E2-replete diabetic rats exhibited 
greater upregulation of cardiac estrogen receptor α (ERα) and reductions in Cx43 
expression and in the phosphorylation levels of the survival molecules pERK1/2 and pAKT. 
While serum APN was reduced independent of sex and ovarian hormone status in all DM, 
cardiac APN was most drastically reduced in DM SO rats. The present translational findings 
are the first to implicate ovarian hormones/E2 in the exacerbated myocardial dysfunction in 
diabetic females, and to suggest a pivotal role for malfunctioning cardiac APN-Cx43 





  There is mounting interest to further understand the role of estrogen (E2) regulation in 
cardiovascular function (Gros et al., 2016; Dworatzek and Mahmoodzadeh, 2017). 
Specifically, there is a need to understand why cardiovascular morbidity and mortality are 
higher in women with type-2 diabetes mellitus (T2DM), compared with age-matched diabetic 
men (Regensteiner et al., 2015). Paradoxically, premenopausal women not only lose their 
inherent E2-mediated cardioprotection, but exhibit exacerbated T2DM-induced cardiac 
anomalies, compared to T2DM men (Juutilainen et al., 2004).  New evidence for a lack of 
negative cardiovascular consequences of E2 replacement therapy (ERT) (Manson et al., 
2017) raises the potential for a rise in cases of exacerbated T2DM associated cardiac 
anomalies.  
  Alterations in E2 receptor (ER) expression (upregulation of ERα and GPER) may 
contribute to sex differences in left ventricular (LV) hypertrophy and heart failure (Regitz-
Zagrosek et al., 2010; Lee et al., 2014). The complex interplay between ER subtypes 
highlights the need to study their expression in the hearts of diabetic females in the absence 
or presence of estrogen. Notably, while ERα knockout mice exhibit disrupted adiponectin 
(APN) signaling (Mauro et al., 2014), there were no studies on cardiac levels of ER subtypes 
or APN in diabetic females. 
  APN, an adipokine with anti-inflammatory and antidiabetic properties (Guo et al., 
2007; Fisman and Tenenbaum, 2014), is reduced in T2DM, and coronary artery disease 
(Zhu et al., 2008; Tian et al., 2009).  Higher APN levels and greater protection of LV function 
from oxidative stress in eNOS deficient mice (Durand et al., 2012) suggest a 
cardioprotective role for APN in female mice. Further, APN supplementation in aged female 
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rats and porcine models reduced myocardial infarct size (Tomicek et al., 2015) and oxidative 
stress (Tao et al., 2007). However, it remained unknown if this sexually dimorphic 
cardioprotection, conferred by APN or its downstream effector connexin43 (Cx43), is 
compromised in DM females.  
  Connexins are widely distributed transmembrane gap junction proteins and Cx43, the 
primary connexin expressed in cardiomyocytes, has emerged as a promising therapeutic 
target for cardioprotection (Bikou et al., 2011; Stauffer et al., 2011). The reduction or 
disorganization of LV Cx43 in heart diseases (Michela et al., 2015) and cardiac dysfunction 
(Lin et al., 2005) support its protective role against cardiac injury. Importantly, while female 
cardiomyocytes exhibit higher levels of Cx43 and its phosphorylated form (Stauffer et al., 
2011) and E2 upregulates Cx43 expression (Moinfar et al., 2016), there are no studies on 
cardiac Cx43 expression, and E2 regulation in diabetic females.  
  The major goal of the present study was to determine if diabetes-evoked myocardial 
dysfunction is more pronounced in female, than male, rats in an E2-dependent manner. 
Further, we tested the hypothesis that disruption of the E2-APN-Cx43 axis underlies this 
sex/E2-specific hypersensitivity to T2DM-evoked myocardial dysfunction. The outcome of 
these findings will identify potential molecular targets for developing novel therapeutics for 
alleviating myocardial dysfunction in DM females. 
 
3.3 Protocols and experimental groups 
  Eight groups of rats (n=8 surviving) divided into 4 pairs (diabetic and control) of sham 
operated (SO), ovariectomized (OVX), ovariectomized with E2 replacement (OVX+E2), and 
male rats. Baseline echo was obtained before treatments and biweekly in all groups. Four 
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weeks after the second STZ injection were allowed for the development of the 
diabetic/hyperglycemic state before the terminal invasive catheterization surgery for 
hemodynamic measurements, and ex vivo studies (Fig. 1).   
3.4 Data analysis and statistics 
  Initially, statistical analysis consisted of two-way ANOVA. Post hoc testing of 
significant findings included the F-test for comparison of diabetic groups vs. control groups, 
and Tukey’s unpaired t-test for evaluation of the estrogen variant groups (Sham, OVX, 
OVX+E2 and male).  Kaplan-Meier survival curves equality was assessed using the 
Wilcoxon’s log-rank test.  Values are expressed as means ± SEM with probability levels less 
than 0.05 to be considered significant.  Prism 5 software (Graphpad Software Inc., San 



































Figure 1. A schematic presentation of high fat diet regimen, diabetes induction, and the 
biochemical and molecular cardiovascular measurements in sex/estrogen variant groups of 






























3.5.1 Higher mortality and heart weight to body weight ratio in diabetic E2 replete 
females  
  Serum E2 levels were lower (P<0.0001) in healthy OVX and male rats compared with 
healthy SO and OVX+E2 rats, and was not affected by TDM in any of the groups (Table 2). 
At the conclusion of the study, diabetic SO and diabetic OVX+E2 exhibited the most 
pronounced mortality (33%) followed by diabetic male (20%) and diabetic OVX (8%) rats vs. 
no mortality in healthy SO, OVX+E2 or OVX groups, and a 10% mortality in healthy male 
rats. The higher mortality in T2DM male rats is consistent with preclinical (Guo et al, 2007) 
and clinical (Regensteiner et al., 2015) findings. Final body weights were similar in diabetic 
and healthy SO or OVX+E2 rats, but lower (P=0.02 and P=0.008, respectively) than those of 
age-matched OVX or male rats (Table 3). The heart weight (HW) to body weight (BW) ratio 
was higher in the diabetic SO (P<0.0001) and OVX+E2 (P=0.02), when compared to 
respective healthy controls. The HW/BW ratio was also significantly higher when compared 
to E2 depleted diabetic groups.  Diabetic sham vs. diabetic OVX (P=0.04) or diabetic male 
(P=0.02), and diabetic OVX+E2 vs. diabetic OVX (P=0.02) or diabetic male (P=0.02) (Table 
3).  
  At the conclusion of the ten weeks (see Fig. 1), echocardiography findings showed no 
change in LV mass or major LV function indices in OVX rats, compared to their healthy 
counterparts (Figs. 2B, 2C and 3) and ejection fraction was not influenced by diabetes or the 
hormonal status (Fig 2A). However, LV mass was higher in diabetic SO (P=0.003), diabetic 
OVX+E2 (P=0.04) and diabetic male (P=0.02) rats, compared with their respective controls 
(Fig. 2C). The findings in the SO and OVX+E2 groups were verified by higher heart 
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weight/body weight ratios (P<0.05, see first paragraph for specific P values) in the healthy 
rat groups, compared to their non-diabetic counterparts (Table 3).  Further, 
echocardiography and directly measured LV function findings reflected significant 
myocardial dysfunction in diabetic E2 replete vs. health groups via two-way ANOVA (Figs. 
2B, 3A and 3B). Diabetic SO (P=0.03) and diabetic OVX+E2 (P=0.02) displayed reduced 
fractional shortening, compared with their respective controls (Fig. 2B). In Fig. 3a, left 
ventricular developed pressure (LVDP) was decreased in diabetic SO vs. healthy SO 
(P=0.009) or OVX+E2 (P=0.04) rats. Fig. 3B shows reduced (P=0.007) dP/dtmax in the 
diabetic OVX+E2 vs. OVX+E2 rats. The study also showed higher (P=0.02) Tau values  in 
diabetic vs. healthy SO groups (Fig. 3C). Echocardiography findings displayed a reduced 
cardiac contractility index (Fig. 3D) in diabetic vs. healthy SO (P=0.003) or OVX+E2 
(P=0.04) rats, which overlaps with the fractional shortening findings from echocardiography 
(Fig. 2B).   
3.5.2 Sex- and diabetes-dependent ER subtype, APN, AdipoR1 responses 
  DM upregulated cardiac ERα (Fig. 4A) in all groups when compared to respective 
controls (SO: P=0.04; OVX: P=0.04; OVX+E2: P=0.01 and male: P=0.02), and upregulated 
GPER (Fig. 4B) in all female groups (SO: P=0.04; OVX: P=0.03 and OVX+E2: P=0.04), but 
not in male rats.  DM did not change (2-way ANOVA) cardiac ERβ (Fig. 4C) or AdipoR1 
(Fig. 4D) expression. In additon to reduced serum APN in all diabetic vs. healthy groups 
(SO: P=0.007; OVX: P=0.02; OVX+E2: P=0.04 and male: P=0.002), the reduction was most 
pronounced in the SO group (Fig. 5A). Notably, cardiac APN was only reduced (P=0.02) in 




3.5.3 Myocardial Cx43, pERK/ERK and pAKT/AKT expressions are reduced in diabetic 
estrogen replete female rats 
   E2-replete diabetic rats exhibited significant reduction in the phosophorylated levels of 
cardiac ERK1/2 (pERK1/2; Fig. 5C) when compared to respective controls (SO: P=0.04 and 
OVX+E2: P=0.01) as well as reduced cardiac levels of the cell phosphorylated survival 
molecule AKT, pAKT (Fig. 5D; SO: P=0.02 and OVX+E2: P=0.04). Finally, cardiac Cx43 was 
reduced in diabetic SO (P=0.0002) or OVX+E2 (P=0.04) vs. their respective control rats, but 
not in the E2 deficient (OVX and male) groups (Figs. 6A and B). The reduction in cardiac 
Cx43 expression was corroborated by the reduced colocalization of Cx43 with the 
scaffolding protein caveolin-3 (cav3) in diabetic vs. SO healthy rats (Fig. 6C). Collectively, 
these molecular findings paralleled the reductions in cardiac function in the same E2-replete 




Table 2. Serum E2 levels in diabetic and control rats (n=8 surviving/group) 
Group Estradiol (pg/mL) 
Sham Operated (SO) 26.72 ± 1.35 
OVX 3.02 ± 0.52* 
OVX+E2 28.47 ± 2.67 
Male 1.22 ± 0.27* 
Diabetic SO 25.74 ± 0.87 
Diabetic OVX 2.54 ± 0.58* 
Diabetic OVX+E2 31.78 ±4.63 
Diabetic Male 1.46 ± 0.26* 
 





Table 3. Heart weight, body weight, the heart weight/body weight ratio and left ventricular 
(LV) mass in diabetic and control groups (n=8 surviving/group) 
Group Heart weight (HW) (g) Body weight (BW) (g) HW/BW Ratio LV mass (mg/kg) 
Sham  0.44 ± 0.02 278.22 ± 8.00 1.60 ± 0.07 1554.00 ± 64.73 
OVX  0.57 ± 0.04 324.00 ± 9.06 1.74 ± 0.09 1736.00 ± 113.30 
OVX+E2  0.54 ± 0.03 293.50 ± 6.40 1.83 ± 0.14 1772.00 ± 150.90 
Male  0.95 ± 0.01# 475.11 ± 10.88# 1.99 ± 0.20 1591.00 ± 101.70 
Diabetic Sham  0.74 ± 0.05 253.40 ± 16.00 3.01 ± 0.21*# 2531.00 ± 315.90*# 
Diabetic OVX  0.56 ± 0.04 313.89 ± 10.37 1.87 ± 0.11 1789.00 ± 103.70 
Diabetic OVX+E2  0.67 ± 0.04  278.13 ± 12.68 2.43 ± 0.19*# 2037.00 ± 67.86*# 
Diabetic Male  0.85 ± 0.07 451.17 ± 21.23# 1.95 ± 0.12 1978.00 ± 96.64 
 
# denotes intergroup significant differences (P<0.05).  The HW/BW ratio and LV mass are 
higher in the diabetic estrogen replete groups, when compared to estrogen depleted groups. 








Figure 2. Effect of diabetic state, after four weeks, on echocardiography-derived ejection 
fraction (A), fractional shortening (B), and left ventricular mass (C). Values are means ± 
SEM (n=8 or 9 surviving/group). *P<0.05 when comparing diabetic vs. respective healthy 

































Figure 3. Effect of diabetic state, after four weeks, on directly measured hemodynamic 
variables via femoral and left ventricular catheterization. Diabetic vs. healthy estrogen 
variant groups display differences in left ventricular developed pressure (LVDP) (A), dP/dtmax 
(B), Tau (C) and contractility index (D).  Values are means ± SEM (n=8 surviving/group). 
*P<0.05 when comparing diabetic vs. respective healthy groups (actual P values are 





























Figure 4. Expression of cardiac estrogen and adiponectin receptors in diabetic and control 
rats. Shown are alterations due to estrogen or sex variations in estrogen receptor alpha; 
ERα (A), G-protein coupled receptor; GPER (B), estrogen receptor beta; ERβ (C), and 
adiponectin receptor 1; AdipoR1 (D). Homogenized left ventricular tissue was analyzed via 
western blot (n=8 surviving/group) and presented as the means ± SEM. Representative 
blots (E) for a particular protein in healthy and diabetic groups were run on the same gel and 
“arbitrary units” is a normalization of the target band to the GAPDH band on the same gel. 
*P<0.05 when comparing diabetic vs. respective healthy groups (actual P values are 

























Figure 5. Diabetes reduces serum adiponectin (APN) in all groups (A) and cardiac APN in 
sham-operated (SO) rats (B) and causes estrogen dependent decreases in ERK1/2 (C) and 
AKT (D) phosphorylation. Measurements in left ventricular tissues were made using ELISA 
(A) and western blot (B-D). Representative blots (E) for a particular protein in diabetic and 
healthy groups were run on the same gel and “arbitrary units” is a normalization of the target 
band to the GAPDH (B), pERK to total ERK (C) and pAKT to total AKT (D). Data presented 
as the means ± SEM (n=8 surviving/group). *P<0.05 when comparing diabetic vs. respective 
healthy groups.  #P<0.05 when comparing sex/estrogen variant groups within the diabetic or 






















Figure 6. Sex/E2-dependent reduction in cardiac connexin43 (Cx43) expression in diabetic 
rats (A) and representative Western blots are shown (B). Representative confocal dual label 
immunofluorescence images of cardiac tissue show reduced expression and colocalization 
of Cx43 (red) with the scaffolding protein Cav3 (green) in diabetic SO vs. healthy SO (C) 
and corroborate the western blot findings.  Values are presented as means ± SEM (n=8 
surviving/group). *P<0.05 and **P<0.001 when comparing diabetic vs. respective healthy 

























  It is currently accepted that T2DM-induced cardiac dysfunction, even in the presence 
of preserved ejection fraction, is associated with higher cardiac morbidity and mortality in 
women than men (Murphy et al., 2017), and our current findings agree with this premise. 
However, the mechanisms of this women’s cardiovascular health problem remained 
unknown most likely due to the lack of preclinical studies that replicated this clinical problem. 
While the increased LV mass is linked to the severity of hyperglycemia, the higher obesity in 
T2DM women might have confounded this sex difference (Rutter et al., 2003). The present 
study is the first to show that diabetic female rats exhibited higher LV mass despite their 
lower body weights, to mimic the greater sensitivity of female rats to diabetes-evoked 
cardiac dysfunction, and the dependence of these detrimental cardiac effects on ovarian 
hormones, particularly estrogen (E2). Our novel findings support the hypothesis that 
disruption of the salutary cardiac APN-Cx43 signaling underlies this sex/E2-dependent 
problem.  
  The high-fat diet and low STZ dose regimen produces clinically relevant slowly 
developing myocardial dysfunction after 10-12 weeks in male rats (Hoit et al., 1999). 
Therefore, it was not surprising that applying the same regimen for only 4 weeks had no 
significant effect on cardiac function in male rats (Figs. 2 and 3). Nonetheless, parallel 
longitudinal echocardiography studies revealed significant myocardial dysfunction in young 
age-matched female rats (8 weeks old at the initiation of the study) subjected to the same 4 
week regimen (Figs. 2 and 3). These findings, along with higher mortality findings are the 
first to mimic the higher sensitivity of women to T2DM-related myocardial dysfunction and 
mortality (Pradhan, 2014; Regensteiner et al., 2015) and support one of the overall study 
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goals. Next, we showed that this clinically relevant problem is dependent on ovarian 
hormones because OVX, similar to male, rats did not exhibit the short-term diabetes-evoked 
myocardial dysfunction and E2 replacement uncovered diabetes-evoked myocardial 
dysfunction (Figs. 2 and 3) and higher mortality in OVX rats. We focused on E2 because it 
paradoxically transforms into a proinflammatory hormone in the presence of oxidative stress 
(White et al., 2005) and diabetes induces oxidative stress (Rochette et al., 2014). 
  Some limitations of echocardiography might have precluded linking increases in LV 
mass to fractional shortening in a clinical study (Rutter et al., 2003). Here, our 
echocardiographic findings, validated and complemented by direct hemodynamic 
measurements of multiple cardiac indices (LVDP, contractility, fractional shortening, Tau, 
dP/dtmax), confirmed the myocardial dysfunction and its dependence on E2 in diabetic female 
rats. Notably, decreased LVDP, contractility index and fractional shortening are signs of 
cardiac dysfunction, while increased LV mass indicates detrimental cardiac remodeling 
(Nagueh et al., 2009; Regitz-Zagrosek et al., 2010).   
  Our findings might reflect the DM-associated heart failure with preserved ejection 
fraction, which is more frequently diagnosed in women (Regitz-Zagrosek et al., 2010; 
Murphy et al., 2017), perhaps due to sex differences in cardiac remodeling processes 
(Dworatzek and Mahmoodzadeh, 2017). We acknowledge that a constant physiological 
plasma E2 level (Table 2) is not identical to the phasic release of endogenous E2 and could 
explain the more exaggerated cardiac dysfunction in diabetic SO vs. OVX+E2 rats. 
Nonetheless, these detrimental cardiac effects in diabetic SO rats reflect the pathological 
outcomes in diabetic women (Pradhan, 2014). While some laboratory tests that confirm 
heart failure without reduced ejection fraction in humans are precluded in rodents due to 
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their high heart rate, the clinical use of BNP for this purpose (Bosseau et al., 2015) can be 
adopted in our future studies. Further, our novel preclinical findings in diabetic OVX+E2 rats 
may be pertinent to diabetic surgical menopause women of child bearing age who are 
usually placed on E2 replacement therapy (Baeza et al., 2010). Also notable as a study 
limitation is that while the diabetic rodent model utlilized in this study resembles, but not 
identical to, human T2DM, and results should be interpreted accordingly. 
  Findings that concomitant ERα downregulation and GPER upregulation inhibit 
vascular remodeling more in females than in males (Lee et al., 2014; Gros et al., 2016) 
indirectly infer detrimental consequences of higher ERα expresssion or its ratio to GPER. 
While the higher cardiac ERα in diabetic rats (Fig. 4A) is consistent with this premise, two 
seemingly discordant findings must be discussed. First, albeit more prominent in SO rats, 
cardiac ERα expression was higher in all diabetic rats irrespective of sex or the hormonal 
status (Fig. 4A) or myocardial (dys)function (Fig. 2). It is likely that the activation of the 
upregulated ERα by endogenous (SO) or exogenous E2 (OVX+E2) expedited cardiac 
dysfunction. Our findings that activation of ERα by E2 or its highly selective agonist mediates 
alcohol-evoked cardiac dysfunction (El-Mas and Abdel-Rahman, 2000; Yao and Abdel‐
Rahman, 2017), and the elevated ERα espresssion in gestational diabetes and heart failure 
(Mahmoodzadeh et al., 2006; Kleiblova et al., 2010) support this premise. Second, the 
activation of the upregulated GPER by E2 might play an additive detrimental role via 
increased LV mass in E2-replete rats (Fig. 2C) because GPER-mediated inhibition of 
cardiomyocyte apoptosis likely expedites cardiac remodeling and heart failure (Gros et al., 
2016). Nonetheless, it is possible that upregulations of ERα and GPER constitute a 
compensatory protective mechanism in diabetes given the recent recognition of GPER as a 
45 
 
major player in sex dependent cardioprotection (Lenhart et al., 2013). More studies in ER 
knockout mice or pharmacological loss or gain of ER subtype function studies (Yao and 
Abdel‐Rahman, 2017) in diabetic rats are needed to address this important issue. 
Collectively, our findings that E2 expedites the progression of diabetes-evoked cardiac 
dysfunction raised the possibility that disruption of E2-dependent cardioprotective molecules 
might contribute to this clinically important problem.   
  We focused on the cardioprotective adipokine, adiponectin (APN), and its 
downstream effector Cx43 because their levels are higher in females (Stauffer et al., 2011), 
and they induce cell survival molecules such as AKT (Fujio et al., 2000; Muslin, 2011).  APN 
and its receptors AdipoR1 and AdipoR2 (Ding et al., 2007) regulate a local cardiac-specific 
APN system to maintain normal myocardial energy homeostasis (Ding et al., 2007; Guo et 
al., 2007). We hypothesized that disruption of this local APN-Cx43 regulated cardiac 
homeostasis might play a critical role in the sex/E2-dependent exacerbation of DM-evoked 
myocardial dysfunction. This premise is supported by AdipoR1 mediation of the APN 
cardioprotective action, and the abrogation of this cardioprotection in diabetes (Li et al., 
2016), at least partly via reductions in AdipoR1 expression or APN level (this study).  
Clinically, while more studies involving adolescents and young women are needed, early 
cardiopulmonary dysfunction has been correlated with low adiponectin levels in adolescents 
with type 2 diabetes (Bjornstad et al., 2016).  
  Physiologically, Cx43 protects cardiomyocyte function and its downregulation, under 
pathological conditions such as diabetes, contributes to heart failure (Michela et al., 2015).  
Notably, remodeling after cardiac pressure overload downregulated cardiac Cx43 
expression via the AMPK pathway (Alesutan et al., 2015) and APN activates the AMPK 
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pathway (Fisman and Tenenbaum, 2014). Therefore, the reduction in cardiac Cx43 
expression (Fig. 6A-C) as a consequence of the reduction in circulating and myocardial APN 
levels (Figs. 4D and 5) likely contributed to the suppressed LV contractility (Fig. 3d) and 
higher mortality in E2-replete diabetic rats. This E2/sex-specific mechanism is supported by 
the lack of similar reductions in cardiac Cx43 expression or in cardiac function in diabetic 
male or OVX rats under the same conditions (Fig. 5). Importantly, prolonged (>10 weeks) 
exposure to diabetes caused cardiac Cx43 disorganization and dysfunction in male rats 
(Hoit et al., 1999; Regensteiner et al., 2015). These findings support the higher sensitivity of 
E2-replete rats to diabetes-evoked myocardial dysfunction, and implicate the dysfunction in 
cardiac APN-Cx43 signaling in this clinically relevant problem.  
  Cx43 confers cardioprotection, at least partly, via activation (phosphorylation) of the 
cell survival molecule AKT and its downstream cardioprotective effecctor, ERK1/2 (Fujio et 
al., 2000; Muslin, 2011). Therefore, we hypothesized that reductions in the phosphorylation 
of AKT or ERK1/2, secondary to reduced Cx43, contribute to the E2-dependent myocardial 
dysfunction in diabetic rats. As ERK activation protects cardiomyocytes from apoptosis 
under oxidative stress (Gong et al., 2015), the reduced phosphorylation of cardiac ERK in 
diabetic E2-replete female rats (Fig. 5C) might contribute, at least partly, to the associated 
cardiac dysfunction (Fig. 2B and Fig. 3). The hypothesis is also supported by the reduction 
in phosphorylated (p)-AKT levels in the hearts of these rats (Fig. 5D) and by the association 
of reduced cardiac p-AKT with disrupted gap junction proteins and cardiac contractile 
dysfunction (Ock et al., 2018). 
      In conclusion, we represented the higher predisposition to, and severity of, diabetes-
evoked cardiac anomalies in women. Our novel findings implicate E2 in the accelerated 
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disruption of cardiac APN-Cx43 signaling as a molecular mechanism for the exacerbated 
cardiac dysfunction in diabetic females. Further, our findings yielded new insights into 
potential therapeutic targets for mitigating the sex-specific exacerbation of cardiac 






CHAPTER FOUR:  RESTORATION OF ADIPONECTIN-CONNEXIN43 SIGNALING AXIS 
REVERSES MYOCARDIAL DYSFUNCTION IN DIABETIC FEMALE RATS  
 
4.1 Abstract 
A cause-and-effect relationship between disrupted cardiac adiponectin (APN)-connexin43 
(Cx43) signaling and the hypersensitivity to type 2 diabetes (T2DM)-evoked cardiomyopathy 
in estrogen (E2)-replete rats has remained elusive. We hypothesized that restoration of the 
APN-Cx43 signaling would alleviate the E2-dependent cardiac dysfunction in diabetic female 
rats. To test this hypothesis, we administered the adiponectin receptor 1 (AdipoR1) agonist 
AdipoRon (30 mg/kg/d) or its vehicle during the last 10 days of an 8-week diabetes mellitus 
(DM) regimen, comprised of a high fat diet and low dose streptozotocin treatment, in sham 
operated (SO) or ovariectomized (OVX) rats; control SO and OVX rats received control diet 
and vehicle for streptozotocin. In DM SO rats, which exhibited left ventricular (LV) and 
autonomic dysfunction, AdipoRon alleviated the: (i) shift to sympathetic dominance 
(increased LF band and LF/HF ratio), (ii) LV hypertrophy, (iii) the reductions in fractional 
shortening (FS), LV developed pressure, dP/dtmax, dP/dtmin and Tau. T2DM had no effect on 
any of these variables in OVX rats. In LV tissues, AdipoRon reversed the reduction in Cx43 
and the elevations in TNFα, hemeoxygenase-1 (HO-1) and circulating Asymmetric 
Dimethylarginine (ADMA) levels. These novel findings yield new insight into a causal role for 
compromised APN-Cx43 signaling in the E2-dependent hypersensitivity to DM-evoked 
cardiac inflammation and dysfunction. Equally important the findings identify restoration of 






  More studies are needed to understand the mechanisms of the paradoxical 
hypersensitivity of women (Regensteiner et al., 2015) and female rats (Leffler and Abdel-
Rahman, 2019) to type-2 diabetes mellitus (T2DM) associated cardiac anomalies despite 
their inherent estrogen (E2)-mediated cardioprotection (Juutilainen et al., 2004). Our recent 
preclinical findings are the first to link E2-dependent disruption of the adiponectin (APN)-
connexin43 (Cx43) signaling to cardiac dysfunction in a model of T2DM (Leffler and Abdel-
Rahman, 2019). However, it remains unknown if such disruption plays a causal role in E2-
regulated molecular responses and the subsequent autonomic and cardiac dysfunction in 
our model system.  
  E2 regulation of its receptor (ER) subtypes contributes to sex differences in 
cardiovascular health and anomalies via modulation of redox enzymes and anti-
inflammatory modulators (Lee et al., 2014). Specifically, while ERα upregulation contributes 
to the higher antioxidant catalase and ALDH2 activities in healthy E2-replete rats (Steagall et 
al., 2017), ERα is paradoxically upregulated in dysfunctional cardiac myocytes of E2-replete 
diabetic female rats (Leffler and Abdel-Rahman, 2019). Further, E2 escalates cardiac G-
protein coupled estrogen receptor (GPER) upregulation in female diabetic rats (Leffler and 
Abdel-Rahman, 2019).  
  The levels of the anti-inflammatory adipokine APN (Guo et al., 2007) are higher in 
healthy (Kadowaki et al.; Zhu et al., 2008), but substantially lower in T2DM rats (Leffler and 
Abdel-Rahman, 2019), in the presence of E2. While the APN receptors (AdipoR1, AdipoR2 
and T-cadherin) exhibit cardiac protective qualities and display gender differences in certain 
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tissues (Iglesias, et al., 2006), their roles are poorly understood.  It is noteworthy that 
reduced APN receptor signaling may constitute an important missing link in our 
understanding of the mechanisms of the adverse outcomes of T2DM (Schernthaner and 
Stangl, 2013) likely due to a compromised cardioprotective cell signaling.   
  APN induces the primary cardiomyocyte connexin, Cx43 (Ruiz-Meana et al., 2008), 
which constitutes a promising therapeutic target (Bikou et al., 2011; Stauffer et al., 2011) for 
alleviating heart diseases (Michela et al., 2015) (Lin et al., 2005). Our recent findings that 
Cx43 is reduced in T2DM female rats along with cardiac dysfunction (Leffler and Abdel-
Rahman, 2019) provided the framework for investigating the potential therapeutic benefits of 
restoring the APN-Cx43 signaling axis in our model system. 
  AdipoRon, an orally active small molecule agonist for AdipoR1 and AdipoR2 has 
been identified as a possible therapeutic for DM (Okada-Iwabu et al., 2013). AdipoRon 
reproduces the effects of endogenous full molecular weight APN, such as activation of 
AMPK signaling, in both male and female mice (Okada-Iwabu et al., 2013) and attenuates: 
(i) post-ischemic myocardial apoptosis (Zhang et al., 2015), (ii) pressure overload-evoked 
cardiac remodeling (Lin et al., 2005; Zhang et al., 2018), and (iii) diabetic nephropathy (Choi 
et al., 2018).  None of these studies, however, dealt with E2-dependent hypersensitivity of 
female animals to DM-evoked cardiac inflammation and dysfunction.   
  The goal of the present study was to determine if AdipoRon mitigates the E2-
dependent exacerbation of cardiac dysfunction in diabetic females. These findings may 
discern a causal role for the cardiac APN-Cx43 disruption in the hypersensitivity to diabetic 
cardiomyopathy and may identify a novel therapeutic modality for alleviating these 




4.3 Protocols and experimental groups 
  Six groups, 3 sham operated (SO) and 3 ovariectomized (OVX) groups, of rats (n=7 
surviving) were divided into 3 pairs as follows (Fig. 1): i. DM SO with AdipoRon or its 
vehicle. ii. DM OVX with AdipoRon or its vehicle. iii control/healthy SO and OVX groups. 
Baseline echocardiography was obtained prior to the initiation of the studies and performed 
biweekly in all groups. After the second STZ dose, four weeks were allowed for the 
development of the diabetic state and AdipoRon (30 mg/kg/d) or its vehicle was 
administered orally during the last 10 days. Thereafter, terminal arterial and LV 
catheterizations were performed for hemodynamic measurements and concluded with 
euthanasia and tissue collection (see Figure 1).   
4.4 Data analysis and statistics 
  Statistical analysis consisted of two-way ANOVA with post hoc testing of significant 
findings including the F-test for comparison and Tukey’s unpaired t-test for evaluation of the 
estrogen variant groups (Control SO, DM SO and DM OVX) and vehicle vs. AdipoRon 
dosing. Values are expressed as means ± SEM with probability levels below 0.05 
considered significant.  Prism 7 software (Graphpad Software Inc., San Diego, CA) was 






4.5.1 Overall mortality of diabetic female rats was not significantly altered with 
AdipoRon dosing 
Consistent with our previous results (Leffler and Abdel-Rahman, 2019), DM SO 
rats had higher mortality compared to DM OVX rats (P=0.01 for OVX vs. DM OVX and 
P<0.001 SO vs. DM SO) (Figure 2A). AdipoRon (30 mg/kg/d; P.O.) had no effect on 
mortality when the drug was administered during the last 10 days of the 8-week DM 
regimen (Figure 2B).  
4.5.2 AdipoRon mitigates the hypersensitivity to autonomic dysregulation in DM 
SO rats 
A physiologically lower (P=0.01) low frequency (LF) nu (Figure 3A) and LF/HF 
ratio (P=0.002) (Figure 3C) in healthy SO than OVX females was negated and 
transformed into higher LFnu (P=0.008) and LF/HF ratio (P=0.004) by DM only in SO 
rats. These findings reflect a shift toward sympathetic dominance in DM SO when 
compared to DM OVX rats (Figure 3). AdipoRon reversed this autonomic abnormality to 
a level that was not different (P>0.05) from SO control levels (Figure 3). 
4.5.3 AdipoRon ameloriated LV hypertrophy in diabetic SO female rats  
  OVX (healthy and DM) rats were heavier (P=0.04) than SO (healthy and DM) rats, 
respectively, and AdipoRon (30 mg/kg/d; P.O.; 10 days) had no effect on body weights of 
DM SO or OVX rats (Fig. 4A). LV mass was higher (P=0.002) in DM SO, but not DM OVX, 
rats, when compared to their healthy controls, and AdipoRon partially, but significantly 
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(P=0.04) reversed this hypertrophy (Figure 4B).  Ejection fraction was not affected by DM in 
SO or OVX rats but was decreased (P=0.03) with AdipoRon in DM SO rats (Figure 4C).   
4.5.4 AdipoRon mitigates cardiac dysfunction in diabetic SO female rats  
  AdipoRon reversed the decrease in fractional shortening (FS) in DM SO rats while 
the lower (P=0.02) FS in OVX rats was not affected by DM in the absence or presence of 
AdipoRon (Figure 4D).  Similiarly, the reductions in LV developed pressure (P=0.03) (LVDP; 
Fig. 5A), dP/dtmax (Figure 5C) and dP/dtmin (P=0.001) (Figure 5D) along with the increase 
(P=0.04) in Tau (Figure 5B), observed in DM SO, but not in DM OVX, rats were reversed by 
AdipoRon. Finally, LV systolic and diastolic end volume, end diastolic pressure (EDP) and 
contractility index (CI) were not altered (P>0.05) with 10 days of AdipoRon administration 
when compared to vehicle-treated DM animals (Table 1).   
4.5.5 AdipoRon reverses ERα upregulation, heightens GPER upregulation and 
restores cardiac Cx43 levels in DM SO females 
  DM upregulated cardiac ERα in SO and OVX rats (P=0.007 and P=0.008; 
respectively), compared to respective controls, consistent with our recent findings (Leffler 
and Abdel-Rahman, 2019), and AdipoRon reversed this upregulation (P=0.02 and P=0.02) 
(Figure 6A). AdipoRon further upregulated GPER (P=0.02) (Figure 6B) and restored Cx43 to 
control levels (P=0.04 SO vs. DM SO and P=0.01 DM SO vehicle vs. DM SO AdipoRon 
dosed) (Figure 6C) only in DM SO females. Interestingly, while these studies showed similar 
downregulation in cardioprotective molecule AKT in DM SO when compared to DM OVX, 
AdipoRon did not alter cardiac levels of AKT in DM SO rats, and further lowered them in DM 




4.5.6 AdipoRon suppresses cardiac expression of AdipoR1 and APN 
AdipoRon, an agonist for AdipoR1, reduced (P=0.002) the LV expression of 
AdipoR1 in DM SO rats (Figure 7A) when compared to healthy SO or vehicle-treated 
DM SO rats.  While DM had no effect, combining DM and AdipoRon reduced (P=0.03) 
AdipoR1 in OVX females (Figure 7A). Consistent with previous studies (Leffler and 
Abdel-Rahman, 2019) cardiac APN was reduced in DM SO and DM OVX females, 
regardless of hormonal status and, here we show further cardiac APN reduction caused 
by AdipoRon in both groups (Figure 7B, C).  
4.5.7 AdipoRon reversed the elevations in ADMA and TNFα in DM SO females  
  Serum asymmetric dimethylarginine (ADMA; Figure 7D) and cardiac TNF 
(Figure 8A) were higher in healthy OVX vs. SO rats (Fig. 8C) (P=0.02 for TNFα; trend 
for ADMA; P=0.06). The greater elevation (P=0.001, SO vs. DM SO and P=.02 OVX vs. 
DM OVX) in ADMA and the increase (P=0.002, SO vs. DM SO) in TNF in DM SO, 
compared with DM OVX (P=0.04), rats were reversed by AdipoRon (P=0.04, DM SO 
vehicle vs. DM SO AdipoRon treated for ADMA levels; Figure 7D) (P=0.03, DM SO 
vehicle vs. DM SO AdipoRon treated for TNFα; Figures 8A). In contrast, the similar 
increases (P<0.05) in heme-oxygenase 1 (HO-1) in DM SO and DM OVX rats were 
reversed by AdipoRon (P=0.02 both; Figure 8B).  HO-1 was increased (P=0.03) in 
healthy OVX vs. healthy SO.  DCF kinetics (Figure 8D) revealed higher cardiac ROS 
levels in both T2DM female groups, regardless of hormone status, when compared to 




Table 1. Cardiac Functional Parameters from Echocardiography (Effect of 4 weeks of 
diabetes on directly measured hemodynamic variables via femoral catheterization). No 
significant differences were found between the estrogen depleted and replete female groups 
after treatment.  Values are means ± SEM; n=7 surviving/group).  s=systolic; d=diastolic. 
 
 LV (s) end volume LV (d) end volume EDP Contractility Index 
Sham Vehicle 
 
34.62 ± 5.02 µL 135.52 ± 12.77 µL 69.46 ± 10.08 mmHg 13.69 ± 1.44 sec-1 
Sham AdipoRon 
 
42.48 ± 6.42 µL 134.92 ± 8.90 µL 75.90 ± 12.09 mmHg 14.41 ± 2.85 sec-1 
OVX Vehicle 
 
44.00 ± 4.07 µL 185.33 ± 9.50 µL 85.37 ± 13.72 mmHg 9.40 ± 2.42 sec-1 
OVX AdipoRon 
 









































Figure 1. A schematic presentation of experimental diet regimen, T2DM induction, dosing 
schedule and the biochemical and molecular cardiovascular measurements in sex/estrogen 





























Figure 2. Kaplan-Meier survival curves for the 9-week study timeline, comparing healthy 
and diabetic SO and OVX females (A) and diabetic SO and OVX females treated with either 
vehicle or AdipoRon (B). *P<0.05 when compared to respective control; **P<0.001 when 

























Figure 3. Spectral indices of heart rate variability measured at the conclusion of the study in 
sham operated (SO) and ovariectomized (OVX) females in the following groups: healthy 
controls, vehicle dosed DM and AdipoRon treated DM. (A) low-frequency (LFnu) (0.25–0.75 
Hz) bands. (B) High-frequency (HFnu) (0.75–3 Hz) bands. (C) The LF/HF ratio depicting 
cardiac sympathovagal balance. Values are means ± SEM of 7 observations. *P<0.05 when 
compared to respective control and +P<0.05 when compared to control sham operated 






























Figure 4. Effect of four weeks of diabetes, on animal body weight (A), echocardiography-
derived left ventricular mass (B), ejection fraction (C) and fractional shortening (D). Diabetic 
E2 replete females (DM SO) display attenuation of detrimental cardiac findings after 
AdipoRon treatment. Values are means ± SEM (n=7 surviving/group). *P<0.05 when 
compared to respective control, **P<0.001 when compared to respective control, #P<0.05 
when compared to DM vehicle-dosed group and +P<0.05 when compared to control sham 






























Figure 5. Effect of four weeks of diabetes, on directly measured hemodynamic variables via 
femoral catheterization. DM SO females display significant differences in left ventricular 
developed pressure (LVDP) (A), Tau (B), dP/dtmax (C), dP/dtmin (D) with AdipoRon treatment 
reversal.  Values are means ± SEM (n=7 surviving/group). *P<0.05 when compared to 
respective control; #P<0.05 when compared to DM vehicle-dosed group. Actual P-values are 

























Figure 6. Expression of cardiac ERs, connexin43 (Cx43) and AKT in control and diabetic 
(vehicle and AdipoRon treated) female rats. Shown are alterations estrogen receptor alpha; 
ERα (A), G-protein coupled receptor; GPER (B), Cx43 (C), and pro-survival molecule pAKT 
(D). Homogenized left ventricular tissue was analyzed via western blot (n=7 surviving/group) 
and presented as the means ± SEM. Representative blots (E) for a particular protein in all 
experimental groups were run on the same gel and “arbitrary units” is a normalization of the 
target band to the GAPDH band or AKT. Molecular weights of proteins are given in kDa. 
*P<0.05 when compared to respective control; #P<0.05 when compared to DM vehicle-




























Figure 7. Diabetes and AdipoRon treatment reduce cardiac adiponectin receptor 1 
(AdipoR1) (A) and adiponectin (APN) (B) expression assessed via western blot in both 
female groups. ADMA levels in serum showed elevations in diabetic animals and attenuation 
in treatment groups via ELISA (C). Representative blots (D) for a particular protein in 
diabetic and healthy groups were run on the same gel and “arbitrary units” is a normalization 
of the target band to the GAPDH. Data presented as means ± SEM (n=7 surviving/group). 
*P<0.05 when compared to respective control, **P<0.001 when compared to respective 



















Figure 8.  Cardiac expression of TNF (A) and HO-1 (B). Quantification of the DCF 
biochemical assay of ROS generation (C), measured by 2′,7′-dichlorofluorescein, in cardiac 
tissue shows the slopes (regression coefficients) of the regression lines in the respective 
healthy and diabetic groups. Values are expressed as means ± SEM (n=7 surviving/group). 
*P<0.05 when compared to respective control, **P<0.001 when compared to respective 
control, +P<0.05 when compared to control sham operated (SO) and #P<0.05 when 





















  While cardiac remodeling is initially a compensatory mechanism to decrease 
ventricular wall stress and maintain cardiac function during cardiac stress, over the long 
term, it is detrimental to heart health and inhibition remains a promising therapeutic goal 
(Nagueh 2009 and Regitz-zagrosek 2010).  Sex differences in cardiac remodeling have also 
been recognized as a limitation to male specific studies (Dworatzek and Mahmoodzadeh, 
2017; Murphy et al., 2017) and ERs play a crucial role in female cardiac health (Steagall et 
al., 2017; Yao and Abdel‐Rahman, 2017).   
  APN has been shown to ameliorate cardiac remodeling in a pathological state 
(Takemura et al., 2007; Tian et al., 2009) and delivery of APN has been suggested as a 
repressor of deteriorating cardiac function (Tao et al., 2007; Zhu et al., 2008; Fisman 
and Tenenbaum, 2014).  However, use of exogenous APN as a therapeutic drug in 
T2DM is obstructed clinically due to its high molecular weight, short half-life and inability 
to administer orally (Kadowaki et al.; Zhang et al., 2018). However, AdipoRon, an orally 
available small molecule agonist for AdipoR1 and AdipoR2, is more clinically feasible 
and has been shown to alleviate post-ischemic cardiac remodeling and apoptosis in 
APN KO male mice (Zhang et al., 2015) and to attenuate cardiac hypertrophy (Zhang et 
al., 2018).  Additionally, AdipoRon ameliorated diabetic nephropathy and oxidative 
stress in male mice (Choi et al., 2018). However, AdipoRon has not been evaluated in a 
female model for cardiac function preservation or attenuation in diabetes mellitus.   
 While this study reproduced the original findings of female hypersensitivity to 
cardiovascular anomalies resulting in higher mortality among E2 replete female diabetic 
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rats (Figure 2A), it did not show a significant reduction in overall mortality when 
comparing vehicle treated to AdipoRon treated groups (Figure 2B). The 10 day course 
of treatment was chosen from supporting literature (Okada-Iwabu et al., 2013; Zhang et 
al., 2018) to address therapeutic investigation (as opposed to prevention).  However, it 
is probable that the length of treatment, only 10 days prior to the termination of the 
study, was insufficient to reduce overall mortality. Several animals were lost from the 
study prior to the initiation of dosing, resulting in a lack of sufficient time to reduce 
mortality.  
  When investigating exacerbated female cardiac effects in diabetes, autonomic 
dysregulation must be considered because autonomic dysregulation/sympathoexcitation 
prediposes  to cardiac dysfunction (De Angelis et al., 2009). To address this question, 
we conducted spectral analysis of inter-beat data obtained the experimental groups 
used in our study. The occurrence of autonomic dysregulation only in E2-replete DM 
rats (DM SO) during the course of our dosing study (Figure 3A and C) supports the 
premise of sympathetic imbalance, linked to E2 modulation.  This DM-evoked autonomic 
dysreguation was partially reversed with the administration of AdipoRon (Figure 3A and 
C) to restore APN-Cx43 signaling.  Heart rate variability suppression contributes to 
cardiovascular morbidity and mortality (Gonzalez-Clemente et al., 2007) and to cardiac 
dysfunction in diabetic male rats rats (El-Sayed et al., 2016), yet this study is the first to 
show the drastic hypersensitivity of females to DM-induced cardiac oxidative stress in 
E2-dependent manner and possibe reversal by APN signaling restoration (Figure 3).  
  Here, we showed that 10 days of AdipoRon treatment (30mg/kg/d; P.O.) had no 
effect on body weight (Figure 4A) or serum APN (not shown), which is consistent with 
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several separate independent study findings (Okada-Iwabu et al., 2013; Choi et al., 
2018; Zhang et al., 2018). However, the increased LV mass shown in the utilized T2DM 
model (Leffler and Abdel-Rahman, 2019) was attenuated with AdipoRon treatment in 
T2DM estrogen replete rats (Figure 4B). Additionally, cardiac functional parameters, 
such as fractional shortening (Figure 4D), LVDP (Figure 5A), and Tau (Figure 5B) were 
significantly improved with activating the APN signaling axis in the E2 replete female 
groups (DM SO), when compared to control animals.  These findings were not 
replicated in the E2 depleted females (DM OVX).  An independent study in male mice 
was consistent with these findings, and showed decreased cardiac hypertrophy post 
aortic banding, decreased fibrosis and decreased BNP levels after AdipoRon treatment 
(Zhang et al., 2018).  In contrast to these E2 specific findings, dP/dtmax (Figure 5C) and 
dP/dtmin (Figure 5D) showed improve functional values in both female groups—some 
reaching significance and some trending, suggesting therapeutic value for AdipoRon in 
all females, regardless of E2 status.   
  Increased ERα expression has been linked to detrimental cardiac effects in 
diabetic humans (Mahmoodzadeh et al., 2006; Kleiblova et al., 2010) and rats (Chung 
et al., 2009) and this was replicated in this study. The AdipoRon dosing reversed ERα 
expression upregulation in both female groups, returning levels to those of healthy 
controls (Figure 6A). It is probable that reduction in ERα expression slowed the 
progression of cardiac dysfunction in all groups and to an even greater degree in E2 
replete females (DM SO).  The findings that estrogen expedites the progression of 
diabetes-evoked cardiac dysfunction raised the question regarding whether disruption of 
physiological E2 cardioprotection may contribute to this clinical problem.  Interestingly, 
75 
 
while ERα expression decreased, GPER expression was further increased with 
AdipoRon treatment.  Increased GPER is cardioprotective (Deschamps and Murphy, 
2009; Li et al., 2015), and may play a role in the attenuation of cardiac dysfunction seen 
in AdipoRon treated DM SO groups (Figure 5).  An imbalance in the ratio of ERα to 
GPER has also been implicated in vascular and cardiac dysfunction (Lee et al., 2014; 
Gros et al., 2016).  It is probable that alteration of the ERs is involved in the attenuation 
process. 
  While Cx43 is physiologically higher in females when compared to males 
(Stauffer et al., 2011) and it induces pro-survival AKT (Fujio et al., 2000; Muslin, 2011), 
both are downregulated in the diabetic female rat model (Leffler and Abdel-Rahman, 
2019). Restoration of APN-Cx43 signaling via the small molecule agonist increased and 
restored cardiac levels of Cx43 in the DM estrogen replete female (DM SO) (Figure 6C), 
accompanied by decreased LV mass (Figure 4B) and restored cardiac function (Figures 
4D and 5).  This was not the case in the E2 deprived females (DM OVX) (Figures 4D, 
5A-D and 6C).  These findings reinforce the link between estrogen and modulation of 
the APN-Cx43 signaling axis. On the contrary, while these expansion studies confirmed 
a decrease in pro-survival cardiac AKT in DM SO when compared to DM OVX, 
AdipoRon dosing did not increase AKT in cardiac tissue (Figure 6D). This lack of 
activated (phosphorylated) AKT may be explained by a diabetic nephropathy study in 
human glomerular endothelial cells following AdipoRon treatment where increases in 
AKT in vitro were found at a concentration of 50 µM daily, but not observed with 
AdipoRon treatment at 10 µM daily (Choi et al., 2018), suggesting that the concentration 
was not high or long enough to produce alterations in cardiac AKT levels.  
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  This study was the first to investigate cardiac APN and AdipoR1 expression in 
AdipoRon treated females.  AdipoR1 levels (Figure 7A) and APN (Figure 7B) were 
decreased in LV tissue in both female groups, when compared to healthy or DM vehicle 
treated animals, which would be expected based on receptor downregulation in the 
presence of increased availability of an agonist. 
  Asymmetric Dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide 
(NO) synthesis (Böger et al., 2009). ADMA has been identified as a strong indicator of 
high cardiovascular risk and overall mortality across broadly defined global human 
populations (Böger et al., 2009; Nemeth et al., 2015; Schlesinger et al., 2016).  ADMA 
causes endothelial dysfunction, vasoconstriction, blood pressure elevation and 
aggravates atherosclerosis and has been identified as a key risk marker clinically to 
assess cardiovascular outcomes (Böger et al., 2009). This study analyzed ADMA levels 
across the six experimental groups and found that while the healthy SO females had 
lower levels of circulating ADMA when compared to control OVX, T2DM more 
drastically raised circulating levels in the SO vs. OVX females (Figure 7C). While 
quantitative values are still debatable, it has been suggested that ADMA plasma 
concentrations above 0.7mol/L indicate substantially increased negative 
cardiovascular outcomes (Böger et al., 2009), our studies found that both diabetic 
female groups had circulating levels above this threshold (mol/L for DM SO and 
mol/L for DM OVX).  In groups where APN signaling was restored, circulating levels 
were reduced below this threshold (Figure 7C), particularly in E2 replete females. 
  Oxidative stress-evoked activation of cardiovascular regulating nuclei underlies 
cardiac sympathetic dominance and subsequent autonomic dysregulation (Kishi and 
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Hirooka, 2012). The latter contributes to cardiac dysfunction in models of human 
diseases including DM although most, if not all, of these studies were conducted in male 
animals (Ceriello and Motz, 2004; Fouda et al., 2018). TNFα was decreased in 
AdipoRon treated females, when compared to vehicle treated females, suggesting 
decreased oxidative stress in the myocardium.  AdipoRon treatment in male mice also 
decreased Angiotensin II induced TGF-β1 expression and cardiac fibrosis (Zhang et al., 
2018), further supporting decreased oxidative stress with APN signaling activation.  
  Exaggerated oxidative stress and proinflammatory molecules (Figures 8A-C) 
likely explain the E2-dependent cardiac sympathetic dominance (Figure 3A and C) and 
cardiac dysfunction (Figure 5) in DM female rats as well as the poor cardiac outcomes 
in DM premenopausal women (Regensteiner et al., 2015). Consistent with a 
physiologically suppressed central sympathetic tone in premenopausal women (Weitz et 
al., 2001), and a neuroprotective role for E2 (Brann et al., 2007), healthy SO rats 
exhibited lower LF domain and LF/HF ratio (Figure 3A and C), indicative of reduced 
sympathetic dominance (Ori et al., 1992), compared to control OVX females. This 
physiologically/clinically relevant finding is likely explained by lower basal levels of ROS 
(Figure 8B and C) and proinflammatory molecules (Figure 8A) in E2-replete rats.  
  While more studies are needed in females and women, it is becoming clear that 
the protective action of APN is lost in diabetes (Li et al., 2016) and support for the E2-
APN-Cx43 signaling axis involvement is increasing. Activation of APN receptors via 
AdipoRon treatment enhances the expression of Cx43 in the heart (Figure 6C), 
improves cardiac function (Figures 4D and 5), and attenuates autonomic dysfunction 
(Figure 3). These findings: cardiac functional data, autonomic regulation data, 
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biochemical alterations and oxidative stress markers all support the E2 modulation of 
the APN-Cx43 signaling axis underlying heightened sensitivity of female rats to 
diabetes-evoked myocardial dysfunction.  Coupled to the findings of a significant overall 
mortality and cardiovascular risk factor in both rats and humans, ADMA, the evidence is 
























CHAPTER FIVE: ADDITIONAL RESULTS AND FINDINGS 
 
5.1 Autonomic Dysfunction in DM SO and OVX+E2 female rats 
 
 Investigation of autonomic regulation via spectral analysis of heart rate variability 
revealed sex/E2-specific adverse cardiac autonomic effects in T2DM rats. DM SO or 
OVX+E2 rats exhibited significant (P<0.05) increases in the R-R oscillations in the LFnu 
range (0.25–0.75 Hz; Figure 1A) and no change in R-R oscillations in the HFnu range 
(0.75–3 Hz; Figure 1B). The resultant higher (P<0.05) LF/HF ratio reflected a shift in the 
cardiac sympathovagal balance toward sympathetic dominance in E2-replete DM 
female, compared to diabetic male or OVX rats (Figure 1C). Importantly, healthy control 
SO and OVX+E2 female rats exhibited lower (P<0.05) LFnu and LF/HF ration (reduced 
sympathetic dominance), compared to male or OVX control rats (Figure 1).  These 
clinically relevant findings over all eight experimental groups yield complementary 
insight into central mechanisms for an E2-dependent autonomic dysregulation, which 
likely contributes to the exacerbated cardiac dysfunction in T2DM females.  
5.2 Mean Arterial Pressure (MAP), Glucose Tolerance Test (GTT) and Survivability  
As part of the research project, blood pressure was recorded in all groups. 
Findings revealed that while healthy males and OVX females had higher baseline blood 
pressures (P<0.05; Figure 2) than estrogen replete females (SO and OVX+E2), end 
point MAP between the control and T2DM groups was not different (P>0.05) (Figure 2). 
Additionally, intravenous glucose tolerance testing (IV GTT), at the conclusion of the 
study, ruled out a role for hyperglycemia in LV hypertrophy (Table 1).  While all DM 
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groups had hyperglycemia, the estrogen replete females (DM SO or OVX+E2) had 
improved glycemic control (Table 1) and LV hypertrophy when compared to OVX 
females or males (Leffler and Abdel-Rahman, 2019).  We concluded that glycemic 
control was not an underlying contributing factor to the hypersensitivity of females to 
DM-evoked cardiac dysfunction. Finally, Kaplan-Meier survival curves for groups (SO, 
OVX, OVX+E2 and Male) in the absence (Figure 3A) or presence of T2DM (Figure 3B) 
revealed the highest all-cause mortality in DM E2-replete rats. 
5.3 Cx43 vs. Cav-3 
Finally, a preliminary study identified a therapeutic potential for targeting 
caveolin-3 (Cav-3) reduced DM-evoked cardiomyopathy in females based on findings 
DM males (Murfitt et al., 2015; Li et al., 2016).  Cav-3 was used as a scaffolding protein 
in confocal immunofluorescent studies in the first phase of this research project. As a 
follow up, LV Cav-3 was quantified (western blot).  Cav-3 was only downregulated 
(P<0.05) in DM male rats (Figure 4), but not in females regardless of their hormonal 
status or cardiac dysfunction (Leffler and Abdel-Rahman, 2019).  In contrast, Cx43 was 
downregulated in estrogen replete DM females (Leffler and Abdel-Rahman, 2019) in 
agreement with findings in DM men and male rats (Ruiz-Meana et al., 2008; Ock et al., 
2018) along with cardiac dysfunction. These findings complemented the study 







Table 1. Intravenous Glucose Tolerance Test Results  
  Group 
Time  Sham OVX OVX+E
2



















































































































Figure 1. Spectral indices of heart rate variability measured at the conclusion of the study 
in the following DM and respective control groups: male, ovariectomized (OVX), sham 
operated (SO), and OVX with E2 supplementation (OVX+E2). (A) low-frequency (LFnu) 
(0.25–0.75 Hz) bands. (B) High-frequency (HFnu) (0.75–3 Hz) bands. (C) The LF/HF ratio 
depicting cardiac sympathovagal balance. Values are means ± SEM of 10 observations. 











































Figure 2. Endpoint mean arterial pressure (MAP) via invasive direct hemodynamic 
monitoring at the conclusion of the study; no significance (P>0.05) between diabetic and 































Figure 3. Kaplan-Meier survival curves for the 9-week study timeline, comparing healthy 































Figure 4. Comparison of Cardiac Expression of Cav-3 and Cx43 with a quantitation of 
cardiac Cav-3 (top) and Cx43 (bottom) in diabetic (dark bars) and control rats. 
Homogenized left ventricular tissue was analyzed via western blot and normalized to 
GAPDH.  Data are presented as means ± SEM (n=8 surviving/group). *P<0.05 when 
compared to respective control, **P<0.001 when compared to respective control, 




















CHAPTER SIX: GENERAL DISCUSSION AND SUMMARY 
6.1 Phase I (Chapter 3) 
  In the first part of this research project, the goal of creating a female rodent model 
that mimicked the higher cardiac morbidity and mortality in T2DM women than in T2DM men 
(Murphy et al., 2017) was achieved.  The research revealed novel data suggesting that 
ovarian hormones, particularly estrogen (E2), accelerate the disruption of physiologically 
protective cardiac APN-Cx43 signaling as a underlying molecular mechanism for the 
exacerbated cardiac dysfunction in diabetic females.  The second phase of the study built 
on the establishment of heightened cardiac dysfunction to elucidate the role of the 
inflammatory microenvironment in this problem using pharmacological and molecular 
approaches. 
6.1.1 Replication of women’s hypersensitivity to DM-evoked cardiac anomalies in 
a female rodent model 
  The selected high-fat diet and low STZ dose regimen produces clinically relevant 
T2DM associated cardiac dysfunction after 8-10 weeks in male rats (Hoit et al., 1999). This 
study reproduced this cardiac dysfunction in female rats after only 4 weeks (Figure 2 and 3). 
These findings, along with higher mortality (Figure 5.3) are the first to mimic the higher 
sensitivity of women to T2DM-related cardiac morbidity and mortality (Pradhan, 2014; 
Regensteiner et al., 2015) and support one of the overall research projects goals.  
6.1.2 Ovarian hormones mediate hypersensitivity to DM-evoked cardiac dysfunction  
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  Collectively, study of longitudinal and endpoint echocardiographic findings and 
terminal direct hemodynamic measurements of multiple cardiac indices (LVDP, contractility, 
fractional shortening, Tau, dP/dtmax), confirmed DM-evoked myocardial dysfunction and its 
estrogen dependence in diabetic female rats. Notably, decreased LVDP, contractility index 
and fractional shortening are signs of cardiac dysfunction, while increased LV mass 
indicated detrimental cardiac remodeling (Nagueh et al., 2009; Regitz-Zagrosek et al., 
2010).  Convincingly, these novel results were replicated in the second phase of the 
research project.     
6.1.3 Disruption of APN-Cx43 signaling is a critical ovarian hormone dependent 
molecular mechanism for heightened diabetic cardiac anomalies in females 
  While all molecular ER expression alterations (Figure 4) can not be overlooked, the 
central focus was on the ERα upregulation seen in all DM groups (Figure 4A). It is likely that 
the activation of the upregulated ERα by endogenous (SO) or exogenous (OVX+E2) E2 
expedited and explained why cardiac dysfunction was only observed in the estrogen replete 
experimental groups (Figures 2 and 3). These studies focused on the cardioprotective 
adipokine, APN, and its downstream effector Cx43 because their levels are higher in 
females (Stauffer et al., 2011), and they induce cell survival molecules such as AKT (Fujio et 
al., 2000; Muslin, 2011).  We hypothesized that disruption of APN-Cx43 regulated cardiac 
homeostasis plays a critical role in the sex/E2-dependent exacerbation of DM-evoked 
myocardial dysfunction.  
  APN reduction in T2DM patients and rodent models (Kadowaki et al.; Bjornstad et al., 
2016) was replicated in this study (Figure 5).  Physiologically, Cx43 protects cardiomyocyte 
function and its downregulation, under pathological conditions such as T2DM, contributes to 
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heart failure (Michela et al., 2015).  Therefore, the reduction in cardiac Cx43 expression 
(Fig. 6A-C) as a consequence of the reduction in circulating and myocardial APN levels 
(Figs. 4D and 5) likely contributed to the suppressed LV contractility (Fig. 3D) and higher 
mortality in E2-replete diabetic rats. The lack of similar reductions in cardiac Cx43 
expression or in cardiac function in diabetic male or OVX rats under the same conditions 
(Figure 5) supports this hypothesis.  Cx43 confers cardioprotection, at least partly, via 
activation (phosphorylation) of the cell survival molecule AKT and its downstream 
cardioprotective effector, ERK1/2 (Fujio et al., 2000; Muslin, 2011). The reductions in the 
phosphorylation of AKT or ERK1/2 (Figure 5C and 5D), secondary to reduced Cx43, 
contribute to the E2-dependent myocardial dysfunction in diabetic rats.  
6.2 Phase II (Chapter 4) 
  In the second part of this research project, the studies reproduced the original 
findings of female hypersensitivity to cardiovascular anomalies resulting in higher 
mortality among E2 replete female diabetic rats (Figure 2A). Notably, the chosen 10 day 
AdipoRon regimen (Okada-Iwabu et al., 2013; Zhang et al., 2018) had no effect on 
overall mortality (Figure 2B). It is probable that the length of treatment, only 10 days 
prior to the termination of the study, was insufficient to reduce overall mortality or 
occurred after mortality reached its peak (Figure 2B). Nonetheless, it is noteworthy that 
the study achieved its goal by demonstrating the potential for AdipoRon therapeutic 
utility via reversing (rather than preventing) DM-evoked functional and molecular cardiac 
anomalies.   
  The following are the major findings of the second phase of research studies. 
First, ovarian hormone-dependent reduction in cardiac Cx43 expression is the major 
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cause for the heightened proinflammatory milieu and cardiac dysfunction in DM SO rats. 
Second, AdipoRon restoration of cardiac Cx43 is pivotal for alleviating, at least partly, 
the ovarian hormone-dependent LV inflammation, hypertrophy, and dysfunction. Third, 
while ovarian hormone-independent adverse responses were not sufficient to cause 
autonomic/cardiac dysfunction, AdipoRon also alleviated these adverse effects in DM 
OVX rats. These findings suggest that additive ovarian hormones dependent and 
independent molecular events additively contribute to the SO rats’ hypersensitivity to 
DM-evoked cardiac and autonomic anomalies. Further, the findings identified 
restoration of cardiac Cx43 as a potential therapeutic option for alleviating cardiac 
anomalies in premenopausal or postmenopausal ERT diabetic women.  
6.2.1 Ovarian hormone-dependent reduction of cardiac Cx43 underlies inflammation 
and cardiac dysfunction in E2 replete female diabetic rats 
  These critical studies focused on female rats with (healthy and DM SO rats) and 
without (healthy DM OVX rats) ovarian hormones. Hypersensitivity to cardiac dysfunction 
four weeks post DM induction in DM SO rats included autonomic dysfunction (Figure 3A and 
C), LV hypertrophy (Figure 4B), reduced fractional shortening (Figure 4D), LVDP (Figure 
5A), dP/dtmax (Figure 5C), dP/dtmin (Figure 5D) and increased Tau (Figure 5B).  These 
functional deficits were accompanied by the signficant reduction in cardiac Cx43 (Figure 6C) 
and increases in a proinflammatory environment (see below). These findings were not 
observed in the DM OVX rats, with the exception of reduced dP/dtmax (Figure 5C), perhaps 
suggesting its progression into cardiac dysfunction in this group at a future timepoint. 
  Tumor Necrosis Factor (TNF) α is potent pro-inflammatory cytokine involved in 
diabetic pathogenesis (Yamakawa et al., 2011). TNFα is elevated in the diabetic patients, 
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particularly those with progressively worsening complications (Preciado-Puga et al., 2014) 
and rodent models, and its inactivation ameliorates the associated pathologies (Yamakawa 
et al., 2011).  Further, the TNFα pathway has sex-dependent molecular signaling alterations 
in diabetic mice (Delgado et al., 2019). These sex-dependent molecular studies were 
performed with young, ovarian hormone replete female rodents, whereas our novel studies 
examined SO and OVX female groups. DM SO females had elevated cardiac TNFα (Figure 
8A and C) when compared to DM OVX. The mitigation of this proinflammatory environment 
and cardiac dysfuncction by AdipoRon suggest a greater therapeutic effect in DM SO rats. 
In healthy control animals, the OVX females had higher LV levels of the proinflammatory 
molecule, when compared to SO females (Figure 8A and C). Additionally, elevations in 
asymmetric dimethylarginine (ADMA)(Figure 7D), heme oxygenase 1 (HO-1) (Figure 8B), 
and ROS (Figure 8D) biochemically validate the proinflammatory state of DM SO rats. 
These findings corrobrate and build on the first phase of this research project (Leffler and 
Abdel-Rahman, 2019). 
6.2.2 AdipoRon ameliorates ovarian hormone-dependent LV inflammatory markers, 
hypertrophy and dysfunction 
  APN ameliorates cardiac remodeling in a pathological state (Takemura et al., 
2007; Tian et al., 2009); however, delivery of exogenous APN as a therapy is hindered 
by its short half-life, high molecular weight and oral inactivity (Kadowaki et al.; Zhang et 
al., 2018). AdipoRon is more clinically feasible and alleviates post-ischemic cardiac 
remodeling and apoptosis in APN KO mice (Zhang et al., 2015), attenuates LV 
hypertrophy (Zhang et al., 2018) and ameliorates diabetic nephropathy and oxidative 
stress (Choi et al., 2018). However, AdipoRon therapeutic potential has not been 
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evaluated in a model of female hypersensitivity to DM-evoked cardiac anomalies.  
These studies examined AdipoRon treatment in DM SO and OVX female rats and 
demonstrated mitigation of hormone-dependent LV inflammatory markers, hypertrophy 
and dysfunction (both autonomic and cardiac).  
  The heightened susceptibility of DM SO females to cardiovascular anomalies was 
mitigated by AdipoRon. Specifically, AdipoRon trended toward improvement in autonomic 
dysfunction (Figure 3A and C), attenuates LV hypertophy (Figure 4B), reverses decreases 
fractional shortening (Figure 4D), LVDP (Figure 5A), dP/dtmax (Figure 5C), dP/dtmin (Figure 
5D) and Tau (Figure 5B) in DM SO females. At a molecular level, DM SO females displayed 
restorations of cardiac ERα (Figure 6A and 6E) and Cx43 (Figure 6C and 6E) levels. The LV 
microenvironment indicated decreases in inflammation with AdipoRon reversing elevations 
in TNFα (Figures 8A and 8C), asymmetric dimethylarginine (ADMA)(Figure 7D), and HO-1 
(Figure 8B).   
6.2.3 AdipoRon alleviates ovarian hormone-independent detrimental molecular LV 
alterations 
  Importantly, and perhaps even more convincingly, AdipoRon alleviated both ovarian 
hormones-dependent, and independent, adverse molecular responses.  While cardiac 
dysfunction in male diabetic rodent models develops between 8-10 weeks (Hoit et al., 1999), 
its occurrence after 4 weeks in the presence of estrogen suggests female hypersensitivity to 
this anomaly (Leffler and Abdel-Rahman, 2019).  While DM OVX females in this study 
lacked clinical evidence of cardiac dysfunction, the findings point to an onset at a later 
timepoint, perhaps more in line with the DM timeline in males.  Preceding the cardiac 
dysfunction are biochemical changes at the molecular level, as evidenced by the increases 
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in ERα (Figure 6A) and GPER (Figure 6B) along with a trend toward reduced Cx43 (Figure 
6C) in cardiac tissues. Additional results showed the LV tissue transforming to a 
proinflammatory environment with increased circulating ADMA (Figure 7D), HO-1 (Figure 
8B) and ROS production (Figure 8D) in DM OVX perhaps resulting from escalating the 
consequences of OVX.  These pre-dysfunctional molecular alterations were ameloriated by 
AdipoRon, as evidenced by reversal in ERα upregulation (Figure 6A), trending reductions 
(P=0.05) in circulating ADMA (Figure 7D), and reversal of HO-1 (Figure 8B and 8C).  These 
exciting findings illustrate the feasability of the proposed novel target in all diabetic females, 
regardless of ovarian hormone status.  
6.2.4 Physiological Implications: Sex/Ovarian Hormones-dependent differences 
  The adopted multilevel experimental approach permitted the generation of novel 
molecular findings on ovarian hormones, particularly estrogen, regulation of cardiac 
function. While the overall objective of this research project was to examine the paradox of a 
diabetic pathology, it is important to not overlook key physiologial differences in the healthy 
control (non-diabetic) groups.  Chapter 3 highlighted the differences between control and 
diabetic groups, based upon the research hypothesis investigation.  However, there were 
significant differences (P<0.05) in a variety of integrative (body weight, heart weight, etc.) 
and biochemical (APN, AKT, HO-1, etc.) data sets within the healthy control animal groups.  






Table 1. Physiological Implications: Sex/Ovarian Hormone Dependent Differences.  
(P<0.05 when compared to sham operated within healthy controls.   ↑ indicates an 
increased value, ↓ indicates a decreased value and a blank box indicates no significant 
difference with that experimental group) 
 
  SIGNIFICANT FINDINGS 
VARIABLE FIGURE OVX    OVX+E2 Male 
Fractional Shortening Fig 3.2B ↓  ↓ 
Tau Fig 3.3C   ↑ 
ERβ Fig 3.4C   ↓ 
Serum APN Fig 3.5A   ↓ 
Cardiac APN Fig 3.5B ↓  ↓ 
pErk/Erk Fig 3.5C   ↓ 
pAKT/AKT Fig 3.5D   ↓ 
MAP Fig 5.2 ↑  ↑ 
Body weight Table 3.3  
Fig 4.4A 
↑  ↑ 
Heart weight Table 3.3   ↑ 
LV (d) end volume Table 4.1 ↑   
LF(nu) Fig 4.3A 
Fig 5.1A 
↑  ↑ 
LF/HF Fig 4.3C 
Fig 5.1C 
↑  ↑ 
Cardiac TNFα Fig 4.8A ↑   
Cardiac HO-1 Fig 4.8B ↑   
Survival Fig 5.3   ↓ 






  While more studies are needed in female animals and women, it is becoming 
clear that the protective action of APN is lost in diabetes (Li et al., 2016) and support for 
the E2-APN-Cx43 signaling axis involvement is increasing. The suggested overall 
signaling schematic is presented in Figure 6.1. There are many novel functional and 
molecular findings of this project that support the E2 modulation of the APN-Cx43 
signaling axis as an underlying mechanism for the heightened sensitivity in female rats 
to diabetes-evoked myocardial dysfunction.  The pharmacological evidence obtained 
with AdipoRon suggests that activation of this signaling axis has potential therapeutic 
value in all females although the effect is more evident in the presence of ovarian 
hormones.  The evidence is mounting to support development of a novel therapuetic 

























Figure 1. Suggested Overall Signaling Schematic.  Healthy female signaling in the 
cardiac E2-APN-Cx43 axis (A). The loss of this cardioprotection with the introduction of 
a diabetic pathology, leading to exacerbated myocardial anomalies (B) and the 
amelioration of exacerbated dysfunction with the restoration of APN-Cx43 signaling by 


















1 All results should be interpreted with the understanding that the adopted T2DM 
rodent model mimics human type 2 diabetes, but neither the physiology of a rodent, 
nor the pathology of the disease are identical to the human condition. 
2 The in vivo and ex vivo studies are crucial for understanding the molecular 
mechanisms in an established DM model system, particularly when linking 
biochemical changes to functional alterations. However, our studies may need be 
complemented with in vitro cell culture techniques because in vivo studies decrease 
the ability to intricately isolate and examine cell signaling pathways with precision.   
3 While the ten-day course of treatment with AdipoRon was chosen to examine its 
feasibility as a therapeutic modality and elucidate underlying pathological 
mechanisms, a longer course of treatment could possibly alter overall study 
mortality—a result not found in this research project. 
4 There are limitations for all equipment and this must be acknowledged for the 
echocardiography machine (VEVO 2100-3100) as much of the acquired cardiac 
function data relied heavily on the echo imaging.  This methodology, however, was 
validated by direct invasive hemodynamic monitoring, strengthening the reliability of 
the data. 
5 We acknowledge that a constant physiological plasma E2 level from the 
subcutaneous implantation of an estradiol supplement is not identical to the phasic 
release of endogenous E2. However, this regimen is clinically relevant to women 





Future research projects will build on these findings of this to expand expertise in 
two important areas. First, studies on molecular myocardial signaling of Cx43 and APN 
in healthy and diabetic females.  In addition to the gap junction function, Cx43 
undergoes a mitochondrial import cycle that appears to play an independent role in 
cardioprotection (Ruiz-Meana et al., 2008). Future studies will examine the signaling 
mechanism of the Cx43 mitochondrial import cycle and mitochondrial ROS.  
Additionally, APN regulates mitochondria (Bugger and Abel, 2010; Koentges et al., 
2015) and the mitochondrial and Cx43 content of the heart is higher in females 
(Juutilainen et al., 2004; Stauffer et al., 2011; Pradhan, 2014). This important 
mitochondrial link suggests that expanded studies are needed to investigate the role the 
E2-APN-Cx43 signaling axis plays on cardiac mitochondria. Second, recent evidence 
suggests that adult cardiac myocytes release miRNAs that mediate signal transduction 
to target cells and circulating miRNAs are remarkably stable (Iaconetti et al., 2015). The 
identification of several miRNAs linked independently to Cx43, estrogen, and DM (see 
Table 1), such as miR1, miR22, miR126, and miR130a (Klinge, 2009; Iaconetti et al., 
2015; Le+¦n et al., 2016), asks the question if the combination further contributes to the 
clinical problem. Future studies including miRNAs could shed new light on both clinical 
diagnostic tools for diabetic women with cardiac pathologies and possible novel 
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